 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page2of62Signature Page:
Investigator Statement: 
IhavecarefullyreadProtocol2468entitled “AStudyEvaluating Escalating Dosesof90YͲDOTAͲBC8(antiͲ
CD45)AntibodyfollowedbyAllogeneic StemCellTransplantation forHighͲRiskAcuteMyeloidLeukemia 
(AML)AcuteLymphoblastic Leukemia (ALL),orMyelodysplastic Syndrome (MDS)”(“Protocol”) version
date11/06/2015. 
Iagreetocarryoutmyresponsibilities inaccordance withtheProtocol,applicable lawsandregulations 
(including 21CFRPart312),GoodClinica lPractice:Consolidated Guidance (ICHͲE6),andapplicable 
policiesofFred Hutch.
PrincipalInvestigator: 
Name(typedorprinted):_Brenda Sandmaier, MD_____________________________________________ 
Institution andAddress:_FredHutchinson Cancer Research Center_______________________________ 
_1100 FairviewAvenueN,M/SD1Ͳ100_________________________ ______
_ Seattle,WA98109Ͳ1024_______ ____________ ________________________ 
Phone Number: _206Ͳ667Ͳ4961_______ ________________________ _____________________ 
Signature:_______________________________________________ Date:____________________ ___
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page3of62TABLEOFCONTENTS 

1.0INTRODUCTION ................................................................................................................ 5
2.0BACKGROUND .................................................................................................................. 5
3.0STUDY OBJECTIVES ........................................................................................................... 9
3.1PrimaryObjective ............................................................................................................. 9
3.2Secondary Objectives ....................................................................................................... 9
4.0STUDY DESIGN.................................................................................................................. 9
4.1Description ofStudy......................................................................................................... 9
4.2Endpoints .......................................................................................................................... 9
4.2.1PrimaryEndpoint......................................................................................................... 9
4.2.2Secondary Endpoints ................................................................................................... 9
4.3Stoppi[INVESTIGATOR_007]Rules.................................................................................................................. 9
5.0SUBJECTSELECTION ....................................................................................................... 10
5.2Exclusions ....................................................................................................................... 11
6.0DONORSELECTION ......................................................................................................... 12
7.0INFORMED CONSENT OFSUBJECTANDDONOR........................................................... 12
8.0SUBJECTREGISTRATION ................................................................................................. 12
9.0PLANOFTREATMENT ..................................................................................................... 13
10.0NONͲINVESTIGATIONAL DRUGS,
IRRADIATION, STEMCELLORBONEMARROW 
ADMINISTRATION ...................................................................................................................... 20
11.0ENGRAFTMENT ANDGRAFTREJECTION ........................................................................ 24
12.0EVALUATIONS
................................................................................................................. 25
13.0DEFINITIONS ................................................................................................................... 28
14.0TOXICITIES ANDCOMPLICATIONS .................................................................................. 29
15.0ADVERSEEVENTREPORTING ......................................................................................... 33
16.0DOSEESCALATION .......................................................................................................... 36
17.0STATISTICAL CONSIDERATIONS ...................................................................................... 39
Numberofpatients................................................................................................................... 40
18.0TARGETED/PLANNED ENROLLMENT .............................................................................. 41
19.0TERMINATION OFSTUDY............................................................................................... 41
20.0DATAANDSAFETYMONITORING PLAN......................................................................... 41
21.0DATAMANAGEMENT/CONFIDENTIA
LITY...................................................................... 42
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page4of6222.0REFERENCES ................................................................................................................... 42
APPENDIX A:BEARMAN CRITERIAFORREGIMENͲ RELATEDTOXICITY................................. 50
APPENDIX B:ACUTEGVHDASSESSMENT ............................................................................. 53
APPENDIX C:CHRONIC GVHDGRADING* ............................................................................. 55
APPENDIX D:METHODS USED TOCALCULATE RADIATION ABSORBED DOSESTOPTS........57
APPENDIX E............................................................................................................................... .61
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page5of621.0INTRODUCTION 
Allogeneic hematopoietic celltransplantation (HCT)isawidelyused formoftherapy forpatientswith
hematological malignancies. In 2007,between15,000and 20,000patientsweretreatedwiththis
procedure worldwide according toestimates fromtheInternational BoneMarrowTransplant Registry
(IBMTR).AlthoughHCToftenoffersthebest,and sometimes theonlychanceforcure,theproce dure
toooftenfailstoeradicate thesepati
ents’malignancies orisassociated withfatal toxicities. Itis
therefore important toimprovedisease control fordiseasessuchasadvanced acutemyeloid leukemia
(AML),acutelymphoblastic leukemia(ALL),andhighͲriskmyelodysplastic syndrome (MDS)patients
withoutsubstantially increasing thetoxicityoftheconditioni ngregimenforpatientsundergoing HCT.
Onerecentadvance, radioimmunotherapy (RIT),offersthepotentialtosubstantially improveHCT
preparative regimens. Withtheuseofradiolabeled monoclonal antibodies (Ab) itispossibletodeliver
highdosesofradiationrelatively specifically tobonemarrow(BM),spleen andothersites of
hematological malignancies whilesparing other
organs.3Ͳ34Ourgrouphasmadeconsiderable progress
usingiodineͲ131(131I)radiolabeled Abtoachievethegoalofdevelopi[INVESTIGATOR_007] preparative regimens with
greaterantiͲtumor effects and overall lesstoxicity.Wehaveused131IͲlabeled antiͲCD45 Ab(BC8) to
deliveratleast2Ͳ3ͲfoldmoreradiationtoBM,spleen and sitesofleukemiathantoanycriticalnormal
organ.
Onesignificant barriertoexpanding theseresultstootherclinicalandresearchcentersisthatmany
NuclearMedicine departments havedifficultyhandlinglargequantities of131I.Thisislargelybecause
thehighͲabundance (100%),mediumͲenergygammacomponent of131Iand 8ͲdayphysicalhalfͲlife
requirepatientstobetreatedinradiationisolation,and posesaradiationexposure riskforstaffand
family.To addressthischallenge, wepropose replacing131Iwithanalternative radionuclide tomakeour
approach morefeasibleforPhaseIIstudiesatadditional centers.YttriumͲ90 (90Y)hasbeenselectedas
thetherapeutic radioisotope forthecurrentclinicaltrial because,inpart,itisapure ßͲemitter thatis
commercially availableinhighspecific activityandpurity.Moreover, thebetaparticlesfrom90Yhavea
highͲenergy(Emax=2.28MeV)withagreatertissueͲpenetrating range(upto11mm)that isthoughtto
bemostfavorable fordeposition ofradiationinlargetumormasses.35
Inthisstudywehopetoestablishthesafety,feasibility andoptimized doseof90YͲlabeledantiͲCD45 Ab
(90YͲDOTAͲBC8)inpatientsundergoing RITtreatment inconjunction withastandardreducedͲintensity 
transplant regimenbeforeHCTforrefractory orrelapsedAML orhighͲriskMDS.Thisclinicalresearch
protocol andthedescribed studywillbeconducted incompliance withtheIRBapproved protocol,
associated federalregulations andallapplicableIRBrequirements .
2.0BACKGROUND 
Allogeneic HCTisawidelyused tool forthetreatment ofpatientswithhematological malignancies, 
however, relatively highͲratesofrelapsehavebeenobserved inpatientswithadvanced leukemiaand
highͲriskMDS.EffortstodecreasepostͲHCTrelapse rates havefocusedlargely onintensification of
cytoreductive therapy,eitherbyincreasing thetotal bodyirradiation (TBI)doseoraddingadditional or
alternative chemotherapy. 
Controlled randomized studieshaveshown thatrelapserates canbe
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page6of62reducedbyincreasing theTBIdose.36Ͳ37However, inthesestudiesthenonͲrelapse mortality(NRM)was
increased withthehigherTBIdose,leadingtonoimprovement inoverall survival(OS).
2.1Targetedhematopoietic irradiation delivered byradiolabeled Ab
Althoughstudieshavedemonstrated benefitforimproved tumorcontrolwithescalated dosesof
therapy,thetoxicitiesthatoccurredasaresultofeffortstoincreasethedoseoftherapy canbe
attributed tothenonͲspecific targetingofthetherapeutic agents.36Ͳ37In contrast,theuseofAbͲ
targetedapproaches todeliverradiationspecifically tositesofdisease whilesparingnormalorgans
offershopeforimproved tumorcontrol withminimally increased rates oftoxicity.Hematologic 
malignancies inparticular provide anoptimalsetting inwhichtoinvestigate RIT,giventheirrelative
radiosensitivity and thecomparative easewithwhichcirculating Abcangain access tocellsintheBM,
lymphnodes,andspleen.38Ͳ39
TheefficacyofRITdependsonmanyvariables, includingproperties ofthetargetedantigen(cellsurface
density,accessibility, shedding, heterogeneity ofexpression), thetumor(size,permeability, vascularity, 
andblood flow),andtheAb(bindingsitespecificity, immunoreactivity, invivostability,avidityandrate
ofendocytosis). Although leukemiacellsexpressavarietyoflinea geͲ specificantigensthatmightbe
targeted, CD33, CD45, andCD66 haveemergedasthemostsuccessful antigensfor RITof
leukemia.1,27,30,34,40 Ͳ48InitialRITstudiesbyourgroupforthetreatment ofAMLemployed anantiͲCD33
Abconjugated to131I.42Whileinitiallocalization of131IͲantiͲCD33AbtotheBMwas convincingly 
documented, theretention of131Iinthistissuewas shortbecauseofinternalization oftheAbͲantigen
complex andrapid degradation oftheAbfollowedbyexcretion ofsmall131Imoietiesfromthetumor
cells,contributing toasuboptimal therapeutic result.11,42Other investigators havepursuedRITforAML
bytargetingCD66 whichispresentonmaturinghematopoietic cells,butnotonleukemicblasts.CD66
targetinghasbeenused todeliverhomogenous radiationtonormalcellsthroughout marrow,relyingon
by[CONTACT_112815] irradiation ofleukemicblaststoimprovetheoutcomeofconditioning priortoHCT.43,49
Investigators havefocusedontheCD45 antigenasanattractive alternative targetforRITofleukemia
and MDS.CD45isatyrosine phosphatase expressed asisoformsvarying insizefrom180to220kD.
Thisantigenisexpressed onmorethan70%ofnucleated cellsinnormalBM,withanaveragecopy
numb erofapproximately 200,000mol
eculespercell.11Theabundant expression ofCD45 onvirtuallyall
leukocytes, includingmyeloidand lymphoid precursors inBMand maturelymphocytes inlymph nodes
aswellasmorethan90%ofAML andALLsamples, providesahighnumberofAbbindingsitesinthese
tissuesforpatientsinremission orrelapse.50Ͳ54Available datasuggestthatCD45isnotshed intothe
bloodstream andisnotrapi[INVESTIGATOR_375]internalized.11,52Thoughsomehaveexpressed concernsabouttargeting
anantigenexpressed asbroadlyasCD45, important advantages alsomustberecognized.LineageͲ
specificradiolabeled Abssuchasthosetargeting CD45 maybesuperiortoleukemiaͲspecific
radiolabeled Absforpatientsinremission orrelapsedpatientswithsubclinical involvement of
extramedullary tissues,sinceinthesesettingsisolatedmaligna ntcellsaresurrounded bynormal
hematopoie
ticcells.Because theradiationfromaradionuclide attachedtoanAbboundtothesurface
ofacellcanbeemittedinanydirectionwithinageographic areadefinedbythepathlengthofthe
radionuclide, theisolated malignant cellmayreceiveasigni ficantlygreaterabsorbed doseifth e
surrounding normalcellsaretargetedaswell.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page7of622.2ClinicalstudiesofRITwith131IͲantiͲCD45Ab(BC8)
Wehaveconducted aseriesofPhaseIand IIclinicaltrialsemploying 131IͲBC8inconjunction withhighͲ
dosechemotherapy andHCTforAML,ALL,andMDS.Resultsofthesetrialswillbesummarized briefly.
Ourinitialstudyof131IͲBC8AbinhighͲriskpatients
withadvanced AML,MDS,orALLwas performed to
determine thebiodistribution ofthetargeted
radiotherapy, aswellasestimatetheMTDof
radiationdelivered by131IͲBC8Abwhencombined 
with120mg/kgCYand12GyTBI.30,34When
combined withCYand TBI,theestimated MTDof
radiationdelivered by131IͲBC8Abtotheliver, the
normalorganreceivingthehighest dosewas 10.5
Gy.Basedontheaverageestimates ofradiation
absorbed doses, treatment attheMTDwas
projected todeliversupplemental radiation doses
of24GytoBMand 50Gytospleen.Based on
thesepromising results,thesame regimenwas
giveninaPhaseIIstudyto18patientsfollowedby
CY/TBIand allogeneic HCTfrommatchedrelated(n=9)orunrelated (n=9)donors.
Sevenof18treated
patients(39%)arealive anddiseaseͲfree after periodsupto5.5years.Only1of9patientsreceivinga
BMdosegreaterthan7cGy/mCirelapsed, incontr astto6of9whorelapsedafter
receivingdosesless
than7cGy/mCitoBM(Fig.1).2,55
Sincesignificant supplemental dosesofhematopoietic radiationweretolerated whencombined with
theconventional transplant preparative regimen,
wealsoperformed aseparate PhaseIIstudyof131IͲ
BC8Abcombined withstandardbusulfan(BU) and
CYasapreparative regimenforpatientswithAML
infirstremission.1FortyͲsixpatientsweretreated
with102Ͳ298mCi131Idelivering 5.3Ͳ19(mean11.3)
GytoBM,17Ͳ72(mean29.7)Gytospleen,and3.5Ͳ
5.25Gytotheliver.Theestimated 3ͲyeardiseaseͲ
freesurvival(DFS)and NRMrates were61%and
21%,respectively (Fig.2).Theseresultswere
compared tothose from509similarpatientsinthe
IBMTRtransplanted
usingBU/CYalone.After
adjustingfordifferences inageand cytogenetics, 
thehazardofmortalityamong131IͲBC8treatedpatientswas 0.65timesthatofRegistrypatients(95%CI
0.39Ͳ1.08;p=.09). Theencouraging resultsachievedwith131IͲBC8AbandBU/CYinyounger patientsled
ustoaskhowthisapproach might beappliedtoolder AMLpatients,sincetheoutcomeforAML patients
over 55ispoorusingstandard chemotherapy, witha5Ͳyearsurvivalrate of<10%.56Ͳ58

FIGURE1:Probability ofrelapseforadvanced AML
patientswho received131IͲBC8Abcombined withCY/TBI.
Thicksolidline=dosetoBM>7cGy/mCi;thickdashed
line=dosetoBM<7cGy/mCi.2DosetoBM>7cGy/mCiDosetoBM<7cGy/mCi
FIGURE2:Probability estimates ofDFS,NRM,and
relapseamongallpatientswho received131IͲBC8Ab,
followedbyBU/CY.1
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page8of62OverthepastdecadethereducedͲintensity HCTapproach hasalsobeenappliedtopatientswithAML,
ALLandMDSinorder togain thebenefitofagraftͲvsͲmalignancy effectwithoutthetoxicitiesassociated 
withastandard HCTregimen.59Ͳ72AlthoughthesestudiesmostlyhavebeenlimitedtolowͲriskremission 
patients,relatively highrelapserates remainatherapeutic dilemmainhighͲriskpatients,suggesting that
agraftͲvsͲleukemia (GvL)effectalone maybeinadequate foradvanced patientswithAML.73Ͳ76Given
theminimaltoxicityofthisreducedͲintensity approach, wehypothesized thattheantiͲleukemic effect
maybeimproved bytheadditionof
targeted hematopoietic  irradiation 
delivered by131IͲBC8AbtothelowͲintensity 
conditioning regimen,withoutundue
toxicity.Tothisend weperformed adoseͲ
escalation studyaddingtargeted
radiotherapy toourFLU/TBI reducedͲ
intensityapproach in58highͲriskpatients
over theageof50withadvanced AMLand
highͲriskMDS.In thisstudyweestimated
theMTDofr
adiationdelivered via131IͲBC8
Abtobe24Gytoliverwhencombined with
thereducedͲintensity regimenfor older
patients.Whilethisstudywas notdesigned
toexaminepotentialefficacy,wewere
encouraged bytheobservation thatthe3Ͳ
yeardiseaseͲfree survivalwas 38%for
patientswithactiveleukemia, aratebetterthanseeninthehistoricalexperie n ce(Fig.3).77
2.3Rationale fortheuseofYttriumͲ90labeledantiͲCD45antibody
Wehaveused131Iastheradiolabel inourpriorclinicalstudiesbecauseitwas readilyavailable, thereis
extensive experience withitsmedicaluse,thetechnology fordirectlyradiolabeling Abswithiodineis
wellestablished, and itsgammaͲraycomponent allowsdirect determination oflabeledAb
biodistribution inthepatientafteratracerinfusion.However, thehi ghͲabundance gammaradiation
component of131Irequiresthatpatientsbetreatedinradiationisolation,andposesapotentialradiation
exposure riskforstaffandfamily. Thispresentsamajorlimitation totheexportability ofthismodality. 
Tocontemplate supplanting 131IͲantiͲCD45Abwithanalternative radionuclide forRITofAML,ALL,and
MDSrequirescareful consideration. YttriumͲ90hasbeenselectedasthetherapeutic radioisotope for
thisproposed clinicaltrial because,inpart,itisapureßͲemitterthatiscommercially availableinhigh
specific activityandpurity.Moreover, thebetapartic lesfrom90YhaveahighͲenergywithgreatertissue
penetrating rangethatisthoughttobemostfavorable fordeposition ofradiationinlargetumor
masses.35These favorable characteristics mustbebalanced bythedesirability oflimitinglocalization of
theradiationeffecttoantigen positivecells,and avoidance ofundulyirradiating theBMstromaor
normalby[CONTACT_112815] cells.We investigated whether90Y,whichdoesnotemitanyphotonradiationand
doesnotrequirelongerͲtermradiationisolationofthepatient,mightresultinimproved therapeutic 
ratiosbecauseofitshigherenergybetaparticles(Emax=2.28MeV)andshorterdecay halfͲlife(2.7
FIGURE3:Estimates oftheprobability ofOS,DFS, TRM,andrelapse
amongpatientstreatedattheMTDof24Gyofradiationdelivered to
theliverbythe131IͲBC8Ab,followedbyTBI/FLU.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page9of62days)compared to131I.These nonͲhuman primatestudiessuggested thattheuseof90Yasaradiolabel 
forantiͲCD45 Abresultsinanapproximately similarratioofradiationdelivered totargetascompared to
nonͲtarget tissuesasseenwith131I.78However, theabilitytotreatpatientswith90Ywithoutrequiring
radiationisolation,and thepotentialforimproved homogeneity ofradiationdelivery withintissues
givenitslongerbetaͲparticlepathͲlength,mayprovide therapeutic advantages. 
Thecomplete dosimetry of90YͲDOTAͲBC8Abinhumansisunknown, acceptable biodistributions ofBC8
Ablabeledwitharadiometal haveyettobedemonstrated, andthetoxicityprofileof90YͲDOTAͲBC8
needstobedefined.Moreover, wemustestablishthat BC8Ablabeledwith90Yhasthepotentialto
adequately decreaserelapsedespi[INVESTIGATOR_040]theabsenceofgammaemissions fromthisradionuclide. Asafirst
stepwewilltherefore investigate theuseof90Yasthetherapeutic radionuclide inthisstudy
3.0STUDY OBJECTIVES 
3.1PrimaryObjective 
Toestimate theMTDofradiationdelivered via90YͲDOTAͲBC8whencombined withFLUand2GyTBIasa
preparative regimenforpatientsagedш18withadvanced AML,ALL,andhighͲriskMDS.
3.2Secondary Objectives 
1.Todetermine disease responseanddurationofremission.
2.Todetermine theratesofengraftment anddonorchimerism resultingfromthiscombined
preparative regimen,andtocorrelate levelofdonorchimerism withestimated radiationdoses
delivered tohematopoietic tissuesviaantibody. 
4.0STUDY DESIGN
4.1Description ofStudy
Thisisanopen labelstudyconducted underaninvestigational newdrugapplication (IND)submitted to
theU.S.FoodandDrug Administration (FDA).ThestudyisasingleͲarmtreatment protocol designed to
meettheprimaryobjectivedescribed above.
4.2Endpoints 
4.2.1PrimaryEndpoint 
Theprimarysafetyendpointwillbetheproportion ofpatientswhodevelop gradesIII/IVBearman
relatedtoxicitywithinthefirst100daysfollowing HCT.
4.2.2Secondary Endpoints 
1.Ratesofengraftment, chimerism, nonͲ relapsemortality(NRM)andacuteGvHD.
2.Achievement anddurationofremission. 
3.Overall anddiseaseͲfreesurvivalthrough day100.
4.Estimation ofabsorbed radiationdosestonormalorgans,
marrowandtumor.
4.3Stoppi[INVESTIGATOR_007]Rules
Doseescalation/de Ͳescalation willbeimplemented inthisstudytoachievetheprimaryobjective of
estimating theMTDof90YͲDOTAͲBC8associated withaGradeIII/IV(Bearman) RRTrate of25%.As
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page10of62described furtherunderStatistical Considerations (section17.0),additional stoppi[INVESTIGATOR_007]rulesareinplace
relatedtograftrejectionandrateofgradeIIIͲIVacutegraftversushostdisease (GvHD).
Ifsufficient evidenceexistssuggesting thatthetrue rateofgraftrejectionexceeds20%,theprotocol will
besuspended and reviewed bytheinvestigators and other experts/committees asappropriate to
deter
minewhetherthetrialshouldbeterminated, continued withoutchange,orcontinued with
revisions. Operationally, suspension wouldbetriggeredbygraftrejectionatanyofthefollowing 
observed proportions: 3/5, 4/10,5/15,6/20,8/25,or9/30.Wehavenotseengraftrejectioninanyof
ourpriorstudiesofradiolabeled BC8Ab.
Theproto c
olwillalsobesuspended ifsufficient evidenceexiststosuggestthatthetruerateofgrades
IIIͲIVacuteGvHDatday+100isexcessive (gradedaccording totheestablished criteria described in
Appendix B).Operationally, suspension wouldbetriggeredbyanyofthefollowing observed 
proportions ofGvHD:4/5, 6/10,8/15,10/20,12/25,or14/30.
Proportions ofgraftrejectionandgra
desIIIͲIVacuteGvHDwillbeevaluated after every5thenrolled
patientbecomesevaluable. Eachsuspension rulewillbeevaluated among allpatientsenrolled,
regardless ofthedoseof90YͲDOTAͲBC8administered.
5.0SUBJECTSELECTION 
5.1Inclusions 
1. Patients must haveadvanced AML,ALLorhighͲriskMDSmeetingoneofthefollowing descriptions: 
xAML orALL beyondfirstremission (i.e.,havingrelapsedatleastone time after achieving 
remission inresponsetoatreatment regimen); 
xAMLorALLrepresenting primary refractory disease (i.e.,havingfailedtoachieveremission at
anytimefollowing oneormorepriortreatmentre
gimens);
xAML evolvedfrommyelodysplastic ormyeloproliferative syndromes; or
xMDSexpressed asrefractory anemiawithexcessblasts(RAEB)orchronicmyelomonocytic
leukemia(CMML)byFABcriteria.
2. Patients notinremission musthaveCD45Ͳexpressing leukemicblasts.Patients inremission donot
requirephenotypi[INVESTIGATOR_007] andmayhaveleukemiapreviously docum e
nted tobeCD45negative(because
inremission patients,virtuallyallantibodybindingistononͲmalignant cellswhichmakeup>95%of
nucleated cellsinthemarrow). 
3. Patients must beш18yearsofage.
4. Patients shouldhaveacirculating blastcountoflessthan10,000/mm3(controlwithhydroxyurea or
similaragentisallowed). 
5. Patients musthaveanestimated creatinine clearance greaterthan50/mlperminutebythe
following formula(serumcreatinine valuemustbewithin 28dayspriortoregistration): 
CrCl=(140Ͳage)(WtinKg)x0.85(female)OR1.0(male)
72xserumCr
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page11of626. Patients musthavenormalhepatic function (bilirubin, AST andALT<2timestheupperlimitof
normal).
7. ECOG <2orKarnofskyш70. 
8. Patients must haveanexpectedsurvivalof>60daysandmustbefreeofactiveinfection. 
9. Patients must haveanHLAͲmatched relateddonororanHLAͲmatched unrelated donorwhomeets
standardSeattleCancer CareAlliance(SCCA)and/orNational MarrowDonorProgram(NMDP)or
otherdonorcentercriteria forPBSCorbonemarrowdonation, asfollows:
xRelate
ddonor:relatedtothepatientandgenotypi[INVESTIGATOR_897] orphenotypi[INVESTIGATOR_897] identicalforHLAͲA,B,
C,DRB1andDQB1.Phenotypic identitymustbeconfirmed byhighͲresolution typi[INVESTIGATOR_007].
xUnrelated donor:
xMatchedforHLAͲA,B,C,DRB1andDQB1byhighresolution typi[INVESTIGATOR_007];OR
xMismatched for asingleallelewithoutantigenmismatching atHLAͲA,B,orCasdefinedby
highresolution typi[INVESTIGATOR_007]butotherwise matched forHLAͲA,B,C,DRB1andDQB1byhigh
resolution typi[INVESTIGATOR_007].
xDonorsareexcludedwhenpreexisting immunoreactivity isidentified thatwouldjeopardize 
donorhematopoietic cellengraftment. Thisdetermination isbasedonthestandardprac tice
oftheindividual institution. Therecommended procedure forpatientswith10of10HLA
allelelevel(phenotypic) matchistoobtainpanelreactiveantibody(PRA)screenstoclassI
andclassIIantigensforallpatientsbeforeHCT.IfthePRAshows>10%activity,thenflow
cytome tricorBandTcellcytotoxiccrossmatchesshou
ldbeobtained. Thedonorshould be
excludedifanyofthecytotoxic crossmatchassaysarepositive .Forthose patientswithan
HLAClassIallelemismatch, flow cytometric orBandTcellcytotoxic crossmatchesshould
beobtainedregardless ofthePRAresults.ApositiveantiͲdonorcytotoxiccrossmatch isan
absolutedonorexclusion. 
xPatientanddonorpairshomozygous atamismatche
dalleleinthegraftrejectionvectorare
considered atwoͲallelemismatch, i.e.,thepatient isA*0101andthedonorisA*0102,and
thistypeofmismatc hisnotallowed.
5.2
Exclusions 
1. Circulating humanantiͲmouseantibody (HAMA).
2. Prior radiationtomaximally tolerated levelstoanycriticalnormalorgan,or>20Gypriorradiation
tolargeareasofthebonemarrow(e.g.,externalradiationtherapytowholepelvis).
3. Patients may nothavesymptomatic coronaryarterydisease andmaynotbeoncardia cmed i cations
forantiͲarrhythmic orinotropiceffects.
4. Patients withthefollowing organdysfunction: 
a. Leftventricular ejectionfraction<35%
b. Corrected DLCO<35%orreceivingsupplemental continuous oxygen
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page12of62c. Liverabnormalities: fulminant liverfailure,cirrhosisoftheliverwithevidenceofportal
hypertension, alcoholichepatitis, esophageal varices,hepatic encephalopathy, uncorrectable 
hepatic synthetic dysfunction asevidenced byprolongation oftheprothrombin time,ascites
relatedtoportalhypertension, bacterial orfungalliverabscess,biliaryobstruction, chronic viral
hepatitis, orsymptomatic biliarydisease.
5.Patientswhoareknowntobeseropositive forHIV.
6.
Perceived inabilitytotoleratediagnostic ortherapeutic procedures. 
7. Active CNSleukemiaattimeoftreatment. 
8. Women ofchildbearing potentialwhoarepregnant(EͲHCG+)orbreastfeeding
9. Fertile menandwomenunwillingtousecontraceptives duringandfor12monthspostͲtransplant. 
10. Inability tounderstand orgiveaninformed consent.
6.0DONOR SELECTION 
DonorsmustmeetHLAmatching criteriaasoutlinedinsection5.1.9aswellasstandardSCCA and/or
NMDPorother donorcentercriteria forPBSCorbonemarrowdonation. 
Fortheveryfew occasions whereweidentifyadonorHPCͲA fromanonͲNMDPsource, wehave
procedures inplace through ourunrelated donorofficetocollecttheinformation necessary tocomply
withdonortesting,scree ning,and
declaration ofdonoreligibilityaccording to21CFR1271.Werequire
thatthedonortesting beperformed byaU.S.CLIAapproved laboratory. Intheveryrarecasewherethe
donortestingisnotabletobeperformed inaCLIAapproved laboratory, orthereisconfirmatory testing
thatneedstobeperformed, orforanydonoridentified fromEuropeandatriskforCJD,wenotethison
thedonorscreening formand requirethattheunrelated donorMedicalDirectorortheattending 
physician approves theuseofthedonorHPCͲA productunderUrgentMe
dicalNeed.
7.0INFORMED CONSENT OFSUBJECTANDDONOR
SubjectswillbereferredtoUniversity ofWashington/Seattle Cancer CareAllianceforconsideration of
HCTand willbecompletely evaluated. Theprotocol shouldbediscussed thoroughly withsubject and
family,andallknownrisksshouldbedescribed. Theprocedure andalternative formsoftherapyshould
bepresented asobjectively aspossibleand therisksandhazardsof theprocedure explained. Consent
willbeobtainedusingformsapproved bytheInstitutional ReviewBoardoftheFredHutchinson Cancer
ResearchCenter.Asummary oftheconference shouldbedictatedforthemedicalrecorddetailingwhat
wascovered.
Donorswillbeconsented according toclinicalconsen tingpracticesatSCCA (relateddonors)orNMDP or
atotherdonorcenters(unrelated donors).
8.0SUBJECTREGISTRATION 
Patientswillbeassignedandregistered utilizingtheinstitution’s standard procedures. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page13of629.0PLANOFTREATMENT
9.1GeneralTreatment Plan
Thistrial willassess thesafetyand feasibility ofthisregimenand estimatetheMTDoftheradiation
absorbed dosefrom90YͲDOTAͲBC8thatcanbedelivered inconjunction withFLU,TBI,andallogeneic 
stemcellorbonemarrowrescue.Afterinformed consent,eligibilityconfirmation andregistration, 
patientswillreceiveaninfusionof0.5mg/kgofideal bodyweight ofDOTAͲBC8 tracelabeledwith
~5Ͳ10mCi of111Intoevaluate biodistribution andcalculatetheradiationabsorbed dosestomajor
organsandthewhole body.The subsequent therapyinfusionof90YͲDOTAͲBC8willdeliveranamountof
90Ycalculated nottoexceedthetargetdosetothecriticalnormalorganreceivingthehighestradiation
dose.Thetherapy dosewillbeadministered onapproximately dayͲ12ofthepreparative regimen,
whichwilltypi[INVESTIGATOR_897]beapproximately 1to2weeksafter thebiodistribution dose.Biodistribution 
(dosimetric) infusionsof111InͲDOTAͲBC8willtypi[INVESTIGATOR_897]notrequireinpatientadmission. Patientsmaybe
admitted overnight totheUniversity ofWashington MedicalCenter (UWMC)ortotheUWMCClinical
ResearchCenter (CRC)fortherapeutic dosesof90YͲDOTAͲBC8asneededdepending onindividual 
circumstances. Serumandurinesampleswillbecollectedfromthefirstseveralpatientsenrolledto
determine pharmacokinetics ofradiolabeled DOTAͲBC8.
FLU30mg/m2willbegivenondaysͲ4,Ͳ3,andͲ 2priortotransplant. Patients thenwillreceive2GyTBI
followedbyinfusionofunmanipulated PBSCorbonemarrowonday0.ForGvHDprophylaxis, MMFwill
bedelivered at15mg/kgevery12hoursstartingonday0andcontinuing today+27(forpatien tswith
relateddonors),orevery8hoursstartingonday0and continuing untilday+40andthentaperedand
stoppedonday+96(forpatientswithunrelated donors).CSPwillbedelivered at3.75mg/kgp.o.every
12hoursbeginning ondayͲ3andcontinuing today+56,then ta peredtoday+180(forpatientswith
relateddonors),orcontinuing today+100and thentaperedtoday+180(forpatientswithunrelated 
donors).
Table1showsthegeneraltreatment schemaforpatientsonthisstudy,whichcombines 90YͲDOTAͲBC8
radioimmunotherapy withanestablished nonͲablative regimenofFLU and2GyTBIpriortoPBSCor
bonemarrowinfusion.Tables 2and3show specific treatment schema, includingimmunosuppressive 
regimens, forpatientswithmatchedrelatedandunrelated donors.
TABLE1:Generaltreatment schema.Thedayoftreatment islistedonlytogive aloose timeͲframe.An
individual studycalendariscreatedforeach patient, withmodifications permitted inconsideration of
clinicaland logisticalneeds.Itisanticipated thatstemcellsorbonemarrowwillbeinfused
approximately 12daysafterdeliveryof90YͲDOTAͲBC8.
Day Event
Ͳ21111InͲDOTAͲBC8(~5Ͳ10mCi)traceͲlabeledinfusion
Gammacameraimaging
Ͳ20 BMbiopsy,gammacameraimaging
Ͳ19thruͲ16 Gammacameraimaging
Ͳ1290YͲDOTAͲBC8therapeutic infusion
Ͳ4,Ͳ3,Ͳ2 FLU30mg/m2/d
0 2GyTBI+PBSCorBoneMarrowinfusion
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page14of62
TABLE2:Specifictreatment schemaforpatientswithHLAͲmatched relateddonors.Treatment schema
forPBSCtransplants toestablish mixedchimerism inpatientswithHLAͲidentical relateddonors.
DayͲ21Ͳ 20Ͳ12Ͳ4Ͳ  3Ͳ 2 0b +27+28+56 +84 +180
111InͲDOTAͲBC8a ෽       
BoneMarrowBiopsy/Blood 
Sample෽    
90YͲDOTAͲBC8  ෽      
Fludarabine 30mg/m2/d  භ ෽  භ   
TBI200cGy   භ     
PBSCorBoneMarrow
Transplant භ  
CSP  Start   Taper Stop
MMF    Startc Stop   
Chimerism Evaluationsd    භ  භeභ
BoneMarrowAspi[INVESTIGATOR_337](and
biopsyifneeded)f    භ   භ 

aFollowedbygammacameraimaging immediately postinfusion,andatleasttwoorthreetimestotal
ondaysͲ20throughͲ16.
bDay0shouldbescheduled according tostandardpractice
cFirstdoseshouldbegiven4Ͳ6hoursafterstemcellorbonemarrowinfusion
dChimerism evaluations fromblood atd28,56e,and84
eOnlyif<50% ond28
fSamplesforpathology, andcytogenetic analysis(ifpreviousabnormality). 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page15of62TABLE3:Specifictreatment schemaforpatientswithHLAͲmatched unrelated donors:Treatment 
schemaforPBSCorbonemarrowtransplants toestablishmixed chimerism inpatientswithHLAͲ
phenotypi[INVESTIGATOR_897] matchedunrelated donors.
DayͲ21Ͳ 20Ͳ12Ͳ 4Ͳ  3Ͳ 2 0b +28 +40  +56+84+96+100+180
111InͲDOTAͲBC8a෽       
BoneMarrowBiopsy/Blood 
Sample෽       
90YͲDOTAͲBC8  ෽      
Fludarabine 30mg/m2/d ෽  ෽  ෽    
TBI200cGy  ෽       
PBSCorBoneMarrow
Transplant භ 
CSP  Start  TaperStop
MMF  Startc Taper  Stop
Chimerism Evaluationsd භ භeභ 
BoneMarrowAspi[INVESTIGATOR_337](and
biopsyifneeded)f භ   භ  

aFollowedbygammacameraimaging immediately postinfusion,andatleasttwoorthreetimestotal
ondaysͲ20throughͲ16.
bDay0shouldbescheduled according tostandardpractice
cFirstdoseshouldbegiven4Ͳ6hoursafterstemcellorbonemarrowinfusion
dChimerism evaluations fromblood atd28,56e,and84
eOnlyif<50% ond28
fSamplesforpathology, andcytogenetic analysis(ifpreviousabnormality). 
9.2Investigational DrugProduct
Theinvestigational productforthisstudyisDOTAͲBC8radiolabeled witheither111In(biodistribution 
dose)or90Y(therapydose).DOTAͲBC8isradiolabeled intheradiochemical facilitiesoftheDivisionof
NuclearMedicine attheUniversity ofWashington. Following thelabelingprocedure theradiolabeled
DOTAͲBC8issterilizedbyfiltration andtestedforendotoxin content.
9.3DetailedInvestigational Treatment Plan:Biodistribution Studies
9.3.1111InͲDOTAͲBC8 Administration 
Inorder todetermine themCi90YͲDOTAͲBC8required todeliverthedesireddoseofradiation, each
patientwillundergobiodistribution studiespriortoreceivingatherapydose.Inthebiodistribution step,
patientswillreceiveatraceͲlabeled infusionof111InͲDOTAͲBC8.Gamma cameraimagesand abone
marrowbiopsywillbeobtainedover thenext severaldays.Onetotwoweeks after thebiodistribution 
infusions, patientswillreceiveatherapy infusionof90YͲDOTAͲBC8.
[IP_ADDRESS]111InͲDOTAͲBC8 doseandinfusionrate
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page16of62111InͲDOTAͲBC8willbeadministered atatotal doseof0.5mg/kgidealbodyweightforpatientsator
aboveidealbodyweight, oractualbodyweightforpatientsbelowidealbodyweight.Themixture of
111InͲDOTAͲBC8willbedilutedtoapproximately 25mlandinfusedat7.5mg/hour. 
[IP_ADDRESS]Bloodsample collection 
Blood samples(CMPandCBD)willbeobtainedpreͲinfusion, attheend ofinfusionandonthefirstday
following infusionforCBD, BUN, creatinine, AST,ALT,andbilirubin.
[IP_ADDRESS]Vitalsigns
Vitalsignswillbeobtainedpriortoinfusionof111InͲDOTAͲBC8and monitored every30minutes(+/Ͳ5
minutes)forthefirst2hoursand thenhourly(+/Ͳ15minutes) untiltheinfusioniscomplete ormore
oftenifclinicallyindicated. 
[IP_ADDRESS]Premedication 
111InDOTAͲBC8willbeadministered throughacentral venouscatheter.Premedications willinclude:
xacetaminophen 650mgPO
xdiphenhydramine 25Ͳ50mgIV;maybegivenindivideddosesifdesired(e.g.,35mgfollowedin
onehourby15mg)
xondansetron 8mgIV
xondansetron 8mgIVtoberepeatedevery8hours(+/Ͳ15minute s) untilcompletion ofinfusion.
xhydrocortisone 100mgIV
xhydrocortisone 100mgIVtoberepeatedevery2hours(+/Ͳ15minutes)untilcompletion of
infusion
xgranisetron 1mgPOorIV;ifpatient doesnottolerateondansetron OR
xprochlorperazine 10mgPOorIV;ifpatientdoesnottolerateondansetron 
xD5
½NStostartpriortotheantibodyinfusionandcontinueuntilcompletion ofinfusion
IfgradeII(NCI CTCAEv.4) allergicͲtype toxicityisencountered (see section 14.1.1),theinfusion should
bepaused,thepatient treatedasindicated below,and theinfusion notrestarted untilsymptoms have
subsided. IfGradeIIIallergic toxicityisencountered and doesnotresolveusing measures described 
below,theinfusionmustbeterminated andnotͲrestarted, andthepatient willbeoffprotocol.Ifother
GradeIIorIIItoxicitiesareencountered (seesection 14.1.1),theinfusionmaybeslowed orpaused.If 
toxicitypersistsorprogresses, theinfusionwillbeterminate d.
IfgradeIVtoxicityoccurs,thepatientwill
beoffstudy.
Potentialacutesideeffectsandtheirplannedmanagement areasfollows:
xfever:acetaminophen 650mg(or15mg/kg)POevery4hoursPRN
xrigors:meperidine 25Ͳ
50mgIV(or0.5–1mg/kg)every2Ͳ4hoursPRN
xpruritis:diphenhydramine 25Ͳ50mgPOorIVevery2Ͳ4hoursPRN
xlowblood pressure: upto500mlnormal salinebolusgivenIVover30min.
mayrepeatx1PRN.
xnausea:diphenhydramin e25Ͳ
50mgPOorIVevery2Ͳ4hoursPRN;prochlorperazine 10mgPO
orIVevery6hoursPRN;granisetron 1mgPOorIVevery12hoursPRN
xanxiety:lorazepam 0.5Ͳ2mg(0.05mg/kg)IVevery4hoursPRN
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page17of62xcough,chestorthroattightness, wheezing: diphenhydramine and hydrocortisone maybe
repeated; albuterolnebulizer 2.5–5mguptoevery1Ͳ2hoursPRN
xanaphylaxis: cessation of111InͲDOTAͲBC8infusionandtreatperinstitution standards 
9.3.2Quantitative Imaging
Due topatient variability, themostobjectivewaytoachieveconsistent targetdosesofradiation
exposure inhumantrialsofradioimmunotherapy isbyfirstperforming gammacameraimagingusing
traceinfusionsofradionuclide toassess pharmacokinetics andbiodistribution.26YttriumͲ90 (90Y),apure
betaemitting radiometal, willbeusedasthetherapeutic radionuclide inthisstudy.90Ycannotbeused
forimagingduetothelack ofdiscretegammaemissions inthequantitative imaging window.Therefore, 
111In(~5Ͳ10mCi),whichisagammaemitter,willbeusedforimaging purposes. 
Thebiodistribution oftraceͲlabeled111InͲDOTAͲBC8willbedetermined inamannersimilartothatused
inourprior131I–BC8studies.Beforereceivingtheimagingtestdoseof111InͲDOTAͲBC8, patientswill
havethevolumesofnormal organs(lungs,kidneys,liver, spleen)measured byCTscans.Patientswill
haveatleastthreetofoursetsofgammacameraimagesperformed, beginning onthedayofinfusion:
one setimmediately post111InͲDOTAͲBC8infusion,followedbyanadditional two tothreeimagingtime
pointsover thecourseof5days.Eachimagingsessionwillconsist ofstaticanteriorandposteriorimages
ofthechest,toincludethethyroid andupperhumeri,staticanteriorandposteriorimagesofthe
abdomen, staticanteriorand posteriorimagesofthepelvis,includingtheupper femurs, and anterior
and posteriorimagesofthewhole body.
Duringeach imagingsessionaknown sourceof111Inwillbe
imagedinafixed geometry, inbothstaticand wholebodyscanningmodes, toaccountforradioactive 
decay andtodetermine gammacamerasensitivity.
Dataobtainedfromgammacamerascansfollowing thetraceͲlabeledinfusionsof111InͲDOTAͲBC8willbe
used todetermine the111Inbiodistribution andtocalculatetheamount(mCi)of90Ynecessary todeliver
theprescribed targetamountoftherapeutic 90YͲDOTAͲBC8.Imageswillbeinspected forgeneral
biodistribution ofactivityinthebody,especially liver, kidney, bonemarrowand spleen.Radiation 
absorbed doses(cGypermCi90Yadministered) willbecalculated foralltissuesandorgans(with special
attention tobonemarrow,liver, lung,andkidney)according tomethodsrecommended bytheMedical
InternalRadiation Dose(MIRD)Committee ofTheSocietyofNuclearMedicine usingOLINDAͲEXM
softwareasdescribed inAppendix D.Thesecalculations willbebasedontheorganactivities
deter minedbyquantita
tiveserialgammaͲcameraimagingusingthebiodistribution dataobtainedwith
tracer111InͲDOTAͲBC8forallmajorsourceorgansshowingactivityabove background. Resultsin
absorbed doseperunitadministered activityof90Ywillbereportedforall25targetorganslistedin
OLINDAandforthewholebody.
9.3.3Marrowbiopsies
Aunilateral bone marrowbiopsy(noaspi[INVESTIGATOR_337])willbeperformed intheSCCA Procedure Suite ontheday
after111InͲDOTAͲBC8infusion.Ifthatsampleisjudged tobeinadequate, asecondsamplemaybe
obtainedwithin48hoursoftheinfusion.Thebiopsysection willbecollected usingNOFIXATIVE agents.
Aresearchtechnician fromthePressLaboratory willpreparetheresearchportionand sendthe
remaining portiontoSCCA Pathology formorphology .
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page18of62Smallsectionsfromthebiopsywillbeweighedandcountedusing agammacounterfor111Incontent,
withcomparison toaquantitative standardoftheinfusionmix,allowingcalculation of%injected
dose/gram marrowoflabeled111InͲDOTAͲBC8.
9.3.4Requirements forTherapy
[IP_ADDRESS]HAMAtest
Blood samplesforHAMAtesting willbeobtainedthedaypriortotheplannedtherapeutic 90YͲDOTAͲBC8
infusionandmustbenegativeinorder forthepatient toproceedonstudy.
[IP_ADDRESS]HepaticorRenalToxicity
Blood samplesdescribed undersection [IP_ADDRESS]abovewillbereviewed forevidenceofhepatic orrenal
toxicity.Ifapatientexperiences grade3toxicity,determination ofwhetherthepatientmayproceedto
thetherapydosewillbemadebythePrincipalInvestigator (PI)(ordesignee )inconsulta
tionwiththe
attending physician. Anypatientwhoexperiences grade4hepatic orrenaltoxicitywillbewithdrawn 
fromthestudy.
[IP_ADDRESS]Favorable biodistribution 
Favorable biodistribution (i.e.,radiationdosetomarrow greaterthandosetoliver)isnotrequiredfor
thepatienttoreceiveatherapy doseof90YͲDOTAͲBC8.Inpreviouspatientsreceivingbiodistribution 
dosesonourotherstudies,theestimated dosestomarrowandspleen weregreaterthandosestolung,
kidneyandtotal bodyeveninthose fewpatientswhose marrowdosewas slightlylower thanliverdose.
Therefore, forthisgroupofpatientswho might nottolerateaconventional preparative regimen,wewill
proceedwithatherapyinfusionof90YͲDOTAͲBC8regardless oftheratioofradiationdosedelivered to
marrowcompared toliver.
9.4DetailedInvestigational Treatment Plan:90YͲDOTAͲBC8Therapy
9.4.1Selection of90YͲDOTAͲBC8 dosefortherapy
Thetotal amount of90Yadministered willbeindividualized basedonthebiodistribution ofthetraceͲ111In
labeleddoseineachpatient.Theamountof90Ywillbecalculated todeliverthepredetermined 
radiationdose (depending uponstatusofescalation schedule; seesection16.1)tothenormal critical
organ(almostalwaysliver)predicted toreceivethedoseͲlimitingradiationdose.Foreachpatient,the
activity(mCi)of90Yneededwillbeconfirmed bythePI(ordesignee) andNuclear Medicine subͲ
investigator. Insome patientswithahighbonemarrowtoliverradiationdoseratio, theremaybethe
possibility ofadversely affecting engraftment bydamagetothebonemarrow supportive stroma
resultingfromdelivering toomuchradiation tothemarrow.Thesepatie ntsmayhavethe90Yactivity
limitedtothatwhichwould deliverthecurrentlystipulated maximum dose tomarrow(seesection
16.2).
Table4showsthedoselevelsthatwillbeusedtoestimatetheMTDof90YͲDOTAͲBC8thatcanbe
delivered incombination withFLUplus2GyTBI/CSP/MMF andallogeneic HCT.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page19of62TABLE4:90YͲDOTAͲBC8 Doselevels
Doselevel90YͲDOTAͲBC8
Estimated radiation dosetonormal organ
receiving highestdose(Gy)
1 6
2 8
3 10
4 12
5 14
6 16
7 18
8 20
9 22
10 24
11 26
12 28
13 30
14 32
9.4.2Timingof90YͲDOTAͲBC8 Therapeutic Dose
The90YͲDOTAͲBC8therapeutic dosewillgenerallybeinfusedapproximately 1to2weeks afterthe111InͲ
DOTAͲBC8biodistribution dose,butcanbedelayedfurther ifnecessary becauseofclinical
circumstances (aslongasthepatienthasnotdeveloped HAMA).Atleast6daysistypi[INVESTIGATOR_897]requiredto
allowcalculation ofradiationabsorbed doseandorderingofthetherapeutic doseofisotope.Thedayof
administration ofthetherapydosewillgenerallybeday–12.
9.4.390YͲDOTAͲBC8 administration
90YͲlabeledDOTAͲBC8fortherapywillbeadministered toeach patientusing anantibody doseand
infusionprocedures (including preͲinfusion andPRNmedications) identicaltothoseused fordosimetry 
studiesinthepatient (see section 9.3.1)exceptthat thehydration infusion,givenat200cc/hr,should
startpriortothe90YͲlabeled DOTAͲBC8infusionandcontinuefor2hoursafter theradiolabeled antibody
infusioniscomplete.Patients mayreceivethetherapy infusionasanoutpatient ormaybeadmittedto
thehospi[INVESTIGATOR_307]overnight, depending onindividual circumstances. 90YͲDOTAͲBC8willbeadministered ata
total doseof0.5mg/kgidealbodyweightforpatientsatoraboveidealbodyweight, oractualbody
weight forpatientsbelowidealbodyweight.Themixture of90YDOTAͲBC8willbedilutedtoatleast25
mland infusedat7.5mg/hour.Vital signswillbeobtainedpriortoinfusionand monitored every30
minutes(+/Ͳ5minutes) forthefirst2hoursand then hourly(+/Ͳ15minutes)untiltheinfusionis
complete ormoreoftenifclinicallyindicated .Allappropriate shi eldingandradiationsafetyprecautions 
willbefollowedduringtheadministration. 
Ifnecessary, thepatient,whenable,willbeinstructed indrawing hisorherblood samplesfroma
centralvenouscatheter and intakinghisorherownvital signsusinganautomated blood pressure
machine. Everypatientwillbeinstructed inthesaf
ehandlingofradioactive bodyfluids.All blood,
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page20of62urine,andtissuesamplescontaining radioisotopes willbeclearlyidentified assuch.Samplescontaining 
highlevelsofactivity(>50μCi)willbetransported inshieldedcontainers. All sampleswillbeprocessed 
bypersonnel trainedintheuseofradioisotopes. 
9.5TimingofPBSCorBoneMarrow Infusion
Forpatientswithestimated marrowbiologichalfͲtimesoflessthan96hoursasestimated bythe
biodistribution dose,donorPBSCorbonemarrowwillnormallybeinfusedapproximately 12daysafter
thetherapydoseof90YͲDOTAͲBC8.In theunlikelyeventthatapatienthas anestimated marrow
biologichalfͲtime longerthan96hours,PBSCorbonemarrowinfusionwillbedelayedaccordingly and
theactualnumberofdayspriortoPBSCorbonemarrowinfusionthatthetherapydoseofantibodyis
administered willbeadjusted. Treatmen tsand scheduleassociated withPBSCorbonemarrowinfusion
arefurther described below.
10.0NONͲINVESTIGATIONAL DRUGS, IRRADIATION, STEMCELL ORBONE
MARROW ADMINISTRATION 
10.1Fludarabine 
Fludarabine willbeadministered atadoseof30mg/m2/day ondays–4,Ͳ 3,andͲ 2.Fludarabine will
typi[INVESTIGATOR_897]begivenintheSCCAoutpatient department.
10.2TotalBody Irradiation (TBI)
TBIwillbeadministered atadoseof2Gyperstandard practiceonDay0,followedbyPBSCinfusion.TBI
willnormallybeadministered between11:00a.m. and2:00p.m.toavoidproximity toadministration of
CSP/MMF. 
10.3Collection andInfusionofDonorPBSC
10.3.1GͲCSFAdministration toRelatedDonorsandPBSCCollection 
Related donorswillundergoGͲCSFadministration and PBSCcollection asperSCCA standardclinical
practice. Theprocedures described heremayvaryinaccordance withallowable variances inclinical
activitiesorasrequiredbymodifications totheSCCA Standard PracticeManual.Related donors
typi[INVESTIGATOR_897]willreceiveGͲCSF16μ
g/kg/day for5consecutive daysfromday–4today0.GͲCSFwillbe
administered byasubcutaneous dailyinjectionbeginning 4dayspriortoday0.ThescheduleofGͲCSF
administration andPBSCcollections canonlybeascertained onceday0isidentified. These doses willbe
administered dailyintheSCCAOu
tpatientDepartment. Thetreatment regimenscheduleandthe
scheduleofGͲCSFadministration and PBSCcollections mustbeconfirmed withthepersonnel inthe
apheresis room.PBSCwillbecollected intheafternoon ofday–1,storedintherefrigerator at4°C
overnight, andinfusedonday0.Ifthecollection onday–1containslessthan5.0×106CD34+cellsper
kgrecipi[INVESTIGATOR_841]weight,asecondcollection willbeperformed thefollowing morning andtransfused onday
0.Donorswillpreferably undergoveinͲtoͲvein collections. IfPBSCcannot becollected byavein tovein
technique, apercutaneous Mahurkar catheterwillbeinserted.Generalprocedures willincludetheuse
ofastandardapheresis machine (COBESpectra,Lakewood Colo.),and
processing upto16litersof
whole blood duringthecollection. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page21of6210.3.2GͲCSFAdministration toUnrelated DonorsandPBSCCollection 
TimingofPBSCcollection forunrelated donorsisprearranged throughthedonorcenterwherethe
donorwas procuredand thescheduleofGͲCSFadministration and stemcellcollections canonlybe
ascertained onceday0isidentified. PBSCwillbecollectedaccording tothedonorcentersta ndardsand
thephysician responsible forPBSCcollection willobtaininformed consentfromthedonor.The target
celldoseis5.0x106CD34+cells/kgofpatient weightforunrelated donorstemͲcell collection. Ifthis
collection goal isnotmet,thepatientmaybeinfusedwithallavailablecellsasappropriate in
accordance withstandard practice. Ifthecelldoseisbelow2.5x106CD34+cells/kg,infusionwillbeat
thediscretion oftheattending physician. 
10.4PBSCANDBoneMarrowInfusion
Allpatientswillreceiveunmodified HSCT(PBSCorbonemarrow)infusiononday0ofthetreatment 
regimen.Day0shouldbeonaTuesdaytoThursdaywhenpossible.
10.5Immunosuppression DosingSchedules 
Day–3:BeginCSPat3.75mg/kgPOQ12 hours(or1.5mg/kgIVQ12 hoursiforalpreparation isnot
tolerated). Forpatientswithrelateddonor,continuetoday+56and thentapertoday+180.
Forpatientswithunrelated donor,continuetoday+100andthentapertoday+180.
Day0:BeginMMFat15mg/kgPO(orsame
doseIViforalpreparation isnottolerated).For patients
withrelated donor,continueMMFQ12hourstoday+27.Forpatientswithunrelated donor,
continueMMFQ8hoursuntilday+40andthentapertoday+96.
CSPdoseswillbegivenQ12hours,andMM FdoseswillbegivenQ12 hours(patientwithrelateddonor)
orQ8hours(patientswithunrelated donor).Sincesignificant nauseamayaccompany this
immunosuppression, particularly inthedaysafterTBI,regularlyscheduled antiͲemetictherapy is
recommended forallpatientsforatleastone weekafter transplant. Adjust mentsmaybemadeto
immunosuppression drugs,dosing,&scheduleduetoclinicalreas
ons.Seerecommendations forCSP&
MMFbelow.
10.6Cyclosporine (CSP)
10.6.1Dosing
Forpatientswithmatched relateddonors,CSPisgiven at3.75mg/kgPOQ12hoursfromday–3today
+56,and thenistaperedtoday+180unlessGVHDdevelops. Forpatientswithmatched unrelated 
donors,CSPisgivenfromday–3today+100,and thenistaperedtoday+180 .Ifthereisnauseaand
vomitingatanytime duringCSPtreatment, thedrugshouldbegivenIVat1.5mg/kgQ12 hours.BothIV
andoraldosesofCSParecalculated using theadjustedweight.
10.6.2Monitoring 
Blood pressure, renalfunction (creatinine, BUN),electrolytes andmagnesium willbefollowedatleast
onceperweek,ormoreoftenifclinicall
yindicated, whilereceivingCSP.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page22of6210.6.3DoseAdjustments 
CSPwholeblood “trough”levels(i.e.,justpriortothenext dose)willbeevaluated onday0andadjusted
ifnecessary tomaintainblood levelsthattarget240Ͳ320ng/ml.Dosereductions shouldonlybemadeif
CSPtoxicityispresentoratexcessive levelsintheabsenceoftoxicityatthediscretion oftheAttending 
Physician. FurtherCSPdeterminat
ionsshouldbeperformed twice weeklyuntilCSPisstopped unless
excessive highlevelsaredetectedortoxicityissuspected, inwhich casemorefrequentmonitoring will
beperformed asclinically indicated. Inthisgroupofpatients,close monitoring ofrenalfunctionis
essential. Dosereductions forhighlevelswithouttoxic i
tyshouldbeconservative (e.g.,25%),toavoid
inadequate immunosuppression, particularly inthefirstmonthpostͲtransplant. 
10.6.4DrugInteractions 
DrugsthatmayaffectCSPlevelsinclude:dilantin,phenobarbital (maylowerCSPlevels),steroids,
fluconazole, voriconazole, posaconazole, ketocona zole,cimetidine(mayincreaseCSPlevels).A
comple
teandcurrentlistofdrugsthatmayaffectCSPlevelsmaybefoundintheBMTStandardPractice
Manual.
10.7Mycophenolate Mofetil(MMF)
10.7.1Dosing
Forpatientswithmatched relateddonors,oraladministration ofMMFwillbeat15mg/kgQ12 hours
(30mg/kg/day) fromtheevening ofday0(firstdosetooccur4Ͳ6hoursafter PBSCorbonemarrow
infusion)untilday+27postͲtransplant, atwhich pointitwillbestoppedwithou ttapering.Forpatients
withmatched unrelated donors,oraladministration ofMMFwillbeat15mg/kgQ8hours(45
mg/kg/day), startingonday0andadministered through day+40,atwhich pointitwillbetaperedtoday
+96.Doseswillberoundedtothenearest250mg.IfthepatientcannottolerateoralMMF,the
medication canbeadministered intrav enously atthesame
dose.BothIVandoraldosesarecalculated 
usingtheadjusted weight.
10.7.2DoseAdjustments 
Theprincipaladversereactions associated withtheadministration ofMMFincludediarrhea,leukopenia, 
sepsis,andvomiting. Ifintheclinical judgme ntoftheattending physician th eobserved toxicityisrelated
toMMFadministration, adoseadjustment maybemade.Basedonpreviousorgantransplant studies,
doseadjustments arelikelytooccurbecauseofhematopoietic orgastrointestinal adverseeffects(see
section 14.0“Toxicities andcomplications”). Basedonpreviousexperience inpatientsafter HCT,dose
adjustments arelikelytooccurbecauseofhematopoietic
adverseeffects,inparticular neutropenia. A
thorough evaluation ofneutropenia shouldoccursuchasperipheral blood chimerism studies,marrow
aspi[INVESTIGATOR_1516], andreviewofmarrowsuppressive medications (e.g.bactrim).Ifallotherpotentialcausesof
marrowtoxicityareruledout,doseadjustments willonlybemadeforseve reneutropenia (ANC
<100/mm3for>5days)thatpersistsafter day21postͲtransplant. Dosereductions shouldbe
conservative (20%).Afterday21,theuseofGͲCSFwillbepermitted forneutropenia. Forseveretoxicity
relatedtoMMF(gradeIVneutropenia >5daysrefractory toGͲCSF),MMFmaybetemporarily stopped.
TheMMFshouldberesta rtedat20%r
educeddosewhentheunderlying toxicitysubsides.Intheevent
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page23of62ofgastrointestinal toxicitythatrequiresmedication forcontrolofpersistent vomitingordiarrheathatis
considered tobeduetoMMF,a20%dosereduction willoccurfirstand ifthereisnoimprovement, 
MMFwillbereducedafurther20%.ForsevereG.I.toxicityrelatedtoMMF(severerefractory diarrhea,
orovertgastrointestinal bleeding), theMMFmaybetemporarily stopped.Patientsshouldbeevaluated 
byaGastroenterology consultant anddiscussed withthepri
ncipalinvestigator beforestoppi[INVESTIGATOR_007]MMF.
Doseadjustments willbemadebasedonoccurrence ofMMFtoxicity.

10.8Modifications ofImmunosuppression 
10.8.1Modifications ofimmunosuppression fordiseaseprogression orrelapse
Guidelines providedinthissection areforpatientswhodemonstrate either:i)progression ofstable
disease presentatthetimeoftransplant orii)relapseoftheirunderlying diseasebeforediscontinuation 
ofimmunosuppression hasbeencompleted. Persistence ofstable,underlying disease doesnotinitself
mandateaccelerated taperofimmunosuppression. 
Patientswithprogressive disease defined
asanyevidenceofrelapsebymorphologic orflowcytometric 
evaluation ofabonemarrowaspi[INVESTIGATOR_337]willundergorapid reduction ofimmunosuppression, after careful
evaluation forGvHD, atthediscretion oftheAttending Physician, PrincipalInvestigator, and/orstudy
subͲinvestigat or(s).In
theeventthat patientswithearlydisease progression orrelapsedonothave
GvHD, immunosuppression shouldbediscontinued. 
DLIwillnotbegivenforprogressive orrelapseddisease onthisprotocol,andpatientswithrelapseor
progression wouldbeeligible forother ongoingDLIprotocols ortreatment plans.
10.8.2Modificati onsofimmunosuppressi
onforlowdonorchimerism 
Immunosuppression shouldbediscontinued asperprotocol unlessthepatient developsGVHDorhas
fallingdonorchimerism withoutevidenceofpersistence, progression, orrelapseofdisease. Inthelatter
situation, MMFshouldbecontinued atfulldoseforamonth and thentaperedover amonth.CSP
shouldbecontinued untilMMFisdiscontinued and
thentaperedover 3months.Guidelines for
management ofGvHDareprovidedundersection11.3.
10.9PostͲTransplant GrowthFactors andNeutropenia 
Itisrecommended thatpatientsnotreceivegrowthfactorsduringtreatment withMMFbeforeday21
postͲtransplant becauseofthepossibleriskofpotentiating MMFtoxicitybyforcing moreprogenitor
cellsintoadividingandproliferating state.GͲCSFmaybeadministered topatientswhohavesevere
neutropenia (ANC<100/mm3for>5days)persisting afterday21orifpatientsareneutropenic (ANC
<500/mm3)withactiveinfection. IfANC dropsto<500/mm3thenprophylactic broad spectrum 
antibiotics maybegiven.
10.10Intrathecal TherapyandTreatment ofCNSDisease
ActiveCNSdiseaseattimeoftreatment isanexclusion criterionforthisprotocol;however, patients
withhistoryofCNSdisease willnotbeexcluded.CNS assessment andprophylactic treatment willbe
managed inaccordance withtheSCCA Standard Practice Manual(withtreatment modifications 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page24of62determined bytheAttending Physician ifclinicallyindicated). All patientswillhaveadiagnostic lumbar
puncture performed during theinitialpreͲtransplant workup intheoutpatient department.Patients 
withpasthistoryorsignificant riskofCNSdisease mayreceiveprophylactic intrathecal therapy with
methotrexate (dosepertheStandardPractice Manual).Patients withevidenceofCNSleuke mic
involvement willhaveinstillation ofmethotr e
xate, and willalsobeconsidered bytheAttending 
Physician toreceiveupto18Gy(10fractionsof1.8Gy)cranialorcranialͲspi[INVESTIGATOR_1304]irradiation as
consolidation ifindicated, beginning approximately day32postͲtransplant orassoonasengrafted, 
whichev er
comeslater.
10.11InfectionProphylaxis
Patientswillreceiveprophylaxis forPCP,HSVand Candidaasperstandardpracticemanual.If
amphotericin isrequired,patientsshouldreceiveliposomal orotherlipidͲbasedamphotericin rather
thanregularamphotericin inorder toreduceriskofnephrotoxicity that maycompromise the
administration ofCSP.
11.0ENGRAFTMENT ANDGRAFT REJECTION 
11.1DonorChimerism 
Chimerism testingmethodswillbeinaccordance withStandardPracticeGuidelines, withtiming
consistent withotherreducedͲintensity transplant protocols (e.g.,FHCRC1938).Chimerism evaluations 
willbeperformed onperipheral blood onapproximately days+28,+56 (if<50% atday+28), and+84.
Mixedorfulldonorchimerism willbeevidenceofdonorengraftment. Definitions of mixed andfull
chimerism, aswellasincreasing andlowdonorchimerism, aredescribed inSection13.0.
Patientswhoobtainmixed orfulldonorchimerism after reducedͲintensity HCT,butsubsequent 
chimerism studiescannotdetectgreaterthan5%donorTͲcells(CD3+)asaproportion ofthetotalͲcell 
population, willbedefinedashavingdeveloped graftrejection. 
Graftrejectioncanoccurbecauseofimmunologic rejectionofdonorcells,orbecauseofinadequate 
stromal supportofthegrowth ofdonorcells.The riskofimmunologic graftrejectionisconsidered tobe
lowforthisprotocol basedonpreviousFHCRCmixedchimerism experience inwhichpatientswhohad 
previously receivedintensivechemotherapy had<10%riskofgraftrejection. Inthisprotocol,additional 
immunosuppression maybeprovidedbylymphohematopoietic irradiation from90YͲDOTAͲBC8.
However, intheeventofmarrowstromal damagefromexcessive radiationexposure, patientsmight
haveinadequate hematopoiesis yetnotmeetthepreviously defined criteria forgraftrejection. Every
effortwillbemadetodetermine graftstatusforpatientswithslow recoveryofneutrophils. Forpatients
whoarecriticallyillandnotexpecte dtosurvivetoday+28,aneffortwillbemadetoobtainamarrow
samplepriortodeathinor
dertoascertaingraftstatus.Similarly, chimerism studieswillbeperformed 
priortoday+28ifnecessary. 
Patientswithslow engraftment ofneutrophils shouldbeconsidered fortreatment withhematopoietic 
growth factorasspecifiedinsection13.0.
ThosepatientswithgradeIVthrombocytopenia and
neutropenia after day+21thatlasts>2weeksandisrefractory togrowth factorsupport,intheabsence
ofcontributing cause suchasmedication (e.g.,MMF),sepsis,orCMVinfection, willbeconsidered to
haveneverengrafted.

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page25of6211.2Evaluation ofChimerism 
Atdays+28,+56(ifneeded),and+84,patientswillbeevaluated forlymphoid ormyeloidchimerism in
theperipheral blood.Patientswhohavemixed orfulldonorchimerism atday+56 orlater,and who
haveevidenceofpersistent, progressive orrelapsedAML willbeconsidered onaseparate protocolfor
DLI,withthegoalofmaximizing thepotentialGvLeffect.
Patientswhohavestablemixedorfulldonor
chimerism onday+56,whose disease isstableorresponding, and whoremainonfulldose
immunosuppression willcontinuetobeobserved, and willnotbeconsidered forDLIatthattime.
PatientswithevidenceofGradeIIorgreaterGvHDalsowillnotbeconsidered for
DLI.
11.3Recommended Treatment ofGvHD
AfterreducedͲintensity HCTfrom10/10antigen matchedunrelated donors,theincidence ofgradesII,III
and IVacuteGvHDinpatientswithsustained engraftment hasbeen46%,4%and 0%,respectively. 
AcuteGvHDhasbeenreadilycontrolled inmostpatientswithhighdosecorticosteroids, butPUVA
(psoralen activated ultraviolet light)has beenrequiredonoccasion. Chronic exte nsive GvHDhas
occurredin34%ofpatients.AcuteGvHDand chronicGvHDwillbegradedaccording toestablished 
criteria (Appendices BandC).
11.3.1Patients developi[INVESTIGATOR_007] tGrade2acuteGvHD:
a. CSP7.5mg/kg/day POintwodivideddoses.Ifthere isconcernofGIabsorption, continueCSP
prophylaxis using IVroute(1.5mg/kgQ12hours).
b. Prednisone (upto2mg/kg/day) maybeaddedifsevereGvHDandnoGvHDresponseby72hoursto
oneweekaftertheadditio nofCSP.
c. Patients withlifeͲthreatening gradeIIIorIVacuteGvHDand/orsteroidrefractory acuteGvHDare
eligibleforinstitutional trialsofGvHDtherapy.
11.3.2Patients withclinical extensive chronicGvHD:
LTFUconsultshouldbeobtainedforpatientswithchronic GvHDand determination oftheappropriate 
treatment forchronicGvHDwillbebas edontheLTFUconsultteamrecommendations. 
12.0EVALUATIONS 
12.1PatientPreͲTransplant BaselineEvaluation 
PatientworkͲupwillbeinaccordance withStandardPractice PolicyManual Evaluation Guidelines for
MarrowTransplant Patients, withthefollowing additional requirements: 
a. 10 ccblood inoneredtoptube(10cc)labeled“Protocol 2468”totheLab(D3Ͳ395,ThomasBuilding)
foranalysisofHAMA.
b. CT scanofchestand abdomen forcalculation oforganvolumes(lungs,liver, spleen &kidneys).
Otherimagingstudiesasclinicallyindi
cated.
c. Unilateral bonemarrowbiopsyandaspi[INVESTIGATOR_337]forpathology andcytogenetics* within30dayspriorto
consentsigning/enrollment. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page26of62d. Dataforrelevantprognostic indices(e.g.,RelapsedAMLIndex,IPSS)willberecordedforallpatients.
*Cytogenetics toincludeFISHpanelforAML and MDSpatients;NPM1,CEBPA,FLT3mutations for
AML patientsonly.
Certainbaselinedatacollectedaspartofstandard clinicalworkͲup,includingserumcreatinine, 
estimated creatinine clearance, bilirubin,AST,ALT,leukocyte count,blastcount,orcytopenias chest
xͲrays,andpulmonary functiontests,willalsoberecordedaspartoftheresearchrecord.
12.2PatientEvaluation withDOTAͲBC8Infusions 
xVitalsigns:priortostarting infusion,every30minutes(+/Ͳ5minutes)duringfirst2hoursof
infusion,hourly(+/Ͳ15minutes)forremainder ofinfusion,andasclinicallyindicated. 
xBlood samples:
a. Before and afterinfusion,3cclavendertoptubeforCBC withdifferential, and6ccgreentop
tubeforrenal andliverfunctiontesting.
b. 6ccgreentoptubeforrenalandliverfunctiontestingonedayafterinfusion.
c. 10ccblood inone redtoptube(10cc)totheLab(roomD3Ͳ395 ,ThomasBuilding)forHAMA
onedaypriorto90YͲDOTAͲBC8Therapyinfusion.
d. Samples drawnforpharmacokinetics asdescribed undersection12.3.
12.3Pharmacokinetics (Pk)
12.3.1Timing
Thefirstseveralpatientsenrolledonthestudywillundergocollection ofblood andurinesamplesforPk
studies.InitialPksamplingwillbebasedontheassumption thatthestudydrugwilldistribute according 
toatwoͲcompartment model.Although samplingmaychange withdataaccrual,theinitialsampleswill
becollectedbeforeandafter111In/90YͲDOTAͲBC8administration asfollows:
xBlood:2Ͳ5ccinpurpletoptubestakenprior totreatment, andthenafter treatment at15minutes
(+/Ͳ5minutes)and1Ͳ2hours(+/Ͳ10minutes)postinfusion,andat3Ͳ5additional timepoints within
thefirst72hourspostinfusion.
xUrine:sampleswillbecollecte dduringthefirst2Ͳ3daysfollowing infusion,either asaliquotsfrom
individual voidsorbasedon24Ͳhoururine collection. 
12.3.2Handlingofspecimens 
xBlood samplestobeheld atcollection location forpi[INVESTIGATOR_9107]bythelabtechnician (refrigeration isnot
required). 
xUrinecollections willbemeasured andrecorded, analiquotofuptoapproxima tely2ccremoved
and
storedatroomtemperature (unlessbeingheld over theweekend, inwhichcaserefrigeration is
preferable), andtheremainder doubleͲflusheddown thetoilet.
xItisimportant toprovide thetimeofsamplecollections onthelabelsontubes
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page27of6212.4PatientEvaluations DuringConditioning andforFirst100DaysPostͲTransplant 
See StandardPracticePolicyManualfor"Evaluation Guidelines forTransplant Patients". Datafrom
thesestandardlaboratory studies,other clinicallyindicated studies,and clinicalassessments bythe
primary careteamwillbereviewed regularlytoassess forregimenͲrelatedtoxicity,occurrence of
SeriousAdverseEvents, andother potentialpostͲtransplant complications suchasGvHDandinfections. 
Thefollowing additional studiesandtestswillbeperf
ormed(Table5):
a. Heparinized blood 10cctoforquantitation ofTͲcell,NKͲcelland granulocyte chimerism on
approximately days+28,+56(if<50%onday+28),and+84.
b. Bonemarrowaspi[INVESTIGATOR_337](andbiopsyifunabletoobtainadequate aspi[INVESTIGATOR_337]sample)topathology on
approximatel ydays+28and
+84.Aspi[INVESTIGATOR_337] willbesent ateachtimepointtocytogenetics, if
patient’sdisease hasaknowncytogenetic abnormality and willalsobesentforotherinformative
disease markers.
c. Chronic GvHDscreening betweendays+80and+100postͲtransplant. 
d.10ccbloodinoneredtoptub
e(10cc)tothelab(D3Ͳ395,ThomasBuilding)forHAMAon
approximately day+84.
12.5PatientEvaluations Following 100DaysPostͲTransplant 
Following day+100ordischarge fromtheSCCA,patientswillreturntotheirprimary carephysicians 
undertheguidanceoftheFHCRC/SCCA LongͲTermFollowͲUpAfterHematopoietic StemCellorBone
MarrowTransplant GeneralGuidelines forReferring Physicians. PatientfollowͲupwillbeperformed 
primarilybytheFHCRCLongͲTermFollowͲUpDepartment unde rtheFHCRC/SCCA MasterProtocolfor
Collection of
ClinicalDataandStorageofLeftover Specimens fromPatientsTreatedAccording toFHCRC
Protocols (Protocol#0999.209). Thefollowing datacollectedthroughthismechanism willberecorded
forpurposesofthisstudyat6,9,12,18and24monthspostͲtransplant (Table5).
1.Survival.

2. Disease status.
3. Selected blood counts(WBC,hemoglobin, hematocrit, platelets). 
4. Renal (creatinine, BUN)and hepatic (Bilirubin, AST,ALT) laboratory values.Estimated creatinine 
clearance willbecalculated andrecordedaspartoftheresearchrecord.
5. Presence/treatment ofchronicGVHD.
6. Pulmonary functiontests(12monthspostͲtransplant) 
7. Chest xͲrays (12monthspostͲtransplant) 
8. Secondary malignanci es.

Any ofthesedatathatareunavailable throughstandard longͲtermfollowͲupwillberequested directly
fromthepatientorlocalphysician. AfterthetwoͲyearfollowͲuptime point,wewillcontinuetomonitor
anychangestosurvival,diseasestatus,and secondary malignanci esreportedunderthestandardlongͲ
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page28of62termfollowͲupprotocol,andwillrecordthisdataforlongͲtermanalysisandreporting. Following relapse
ordisease progression, patientswillbefollowedannuallyforsurvivaland development ofsecondary
malignancies. Following othersignificant diagnoses and/ortherapi[INVESTIGATOR_014] thatwould confound assessment 
oftherelationship betweenthestudytreatment andadverseevents(e.g.,furt hertherapyintendedto
maintaindisease remission), patientswillbefollowedannuallyfordiseasestatus,survival,and
development ofsecondary malignancies. 
TABLE5:GeneralSchedule ofPatientEvaluations 
 BaselineDays MonthsAnnual
following 2
years
+28 +56 +84 6 9 121824
HAMA(PressLab)භ    භ       
CT(chest,abdomen)  භ        
BoneMarrowBiopsy/Aspi[INVESTIGATOR_337] to:        
Pathology භaභ  භ      
Cytogenetics භaභbභb  
BloodtoHematopathology/CIL (Chimerism) භcභ භdභ      
GVHDscreening    භe  
Datatrackingforsurvival,diseasestatus,bloodcounts,renalandhepaticlabvalues,
presence/treatment ofchronic GVHD,seriousadverse events,secondary malignancies. භ භ භ භ භ 
Datatrackingforsurvival,diseasestatus,andsecondary malignancies      භ 
aBonemarrowbiopsy/aspi[INVESTIGATOR_337] within30dayspriortoenrollment. 
bSampletocytogenetics ifpatient’sdisease hasknown cytogenetic abnormality.
cBlood maybedrawnpriortobaseline;e.g.,attimeofHLAtypi[INVESTIGATOR_007].
dChimerism atday+56onlyif<50%atday+28.
eGVHDscreening betweenday+80andday+100.
13.0DEFINITIONS
Complete remission: complete resolution ofallsignsofmyelodysplasia orleukemiaforatleastfour
weekswithallofthefollowing: 
1. Normal bonemarrowwithblasts<5% withnormalcellularity, normal megakarypoiesis, morethan
15%erythropoiesis andmorethan25%granulocytopoiesis. 
2. Normalization ofblood counts(noblasts,platelets>100000/mm3,granulocytes >1500/mm3)
3. Noextramedullary disease.
Partialremission :
1. Improvement ofhematological parameters intheperipheral blood
2. 50%declineinmarrowblastsfrompreͲtransplant levelwith>10%erythropoiesis and 25%
granulocytopoiesis. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page29of62Nonresponder :Allpatients notqualifying forcomplete orpartialremission. 
Relapse :
1.AfterCR:>5% blastsinthebonemarrowand/orperipheral blood.Confirmation ofrelapse bybone
marrowanalysiswithmorethan10%blasts.
2.AfterPR:increase ofblastscellsinthemarrowto>50% ofthose during PR.
3.Extramedulla rydisease
confirmed cytologically orhistologically. 
Persistent Disease :
1.>5% blastsinthebonemarrowbyhistology
2.presenceofaclonalpopulation ofmyeloidcellsbyflow
3.persistence/recurrence ofapreviously documented cytogenetic abnormality 
FullChimerism: >95%donorCD3+Tcells.
Mixed Chimerism :thedetection ofperipheral blood donorTcells(CD3+) andgranulocytes (CD33+) asa
proportion ofthetotalperipheral bloodTcellandgranulocyte population, respectively. 
Increasing DonorChimerism: anabsoluteincreaseof20%ofCD3+Tcellsoverthechimerism evaluation 
ofthepreviousmonth.
Decreasing DonorChimerism :decreasing donorchimerism isdefinedasanabsolutedecrea seofatleast
20%ofCD3+Tcellchimerism over thepreviousmonth.
LowDonorChimerism :lowdonorchimerism isdefinedas<40% CD3+Tcellsafter HSCT.Low donor
chimerism shouldalwaysbeconfirmed withrepeatperipheral blood Tcellandgranulocyte chimeris m
analysis.
GraftFail
ure:Primarygraftfailure isdefinedasfailure toachieveneutrophil engraftment (ANC>500/μL)
inpatientssurvivingatleast 28days;secondary graftfailure asneutrophil recoveryfollowedbyadecline
inANC to<500/μ Lunresponsive togrowthfactorstimulation. 
14.0TOXICITIES ANDCOMPLICATIONS 
14.1111In/90YͲDOTAͲBC8
Twoseparate typesoftoxicitiesareanticipated withtheuseofradiolabeled DOTAͲBC8:acutetoxicities
associated withmonoclonal antibodyinfusion,andlongertermtoxicitiesassociated withradiationdose.
14.1.1Acute toxicityassociated withDOTAͲBC8 infusion
Theprimaryacutetoxicitiesassociated withadministration oftheBC8Abareallergic reactions. Allergic
reac
tionstoadministration offoreignproteinmayresultinfever,chills/rigors, hypotension, pruritis,
urticaria,allergicrhinitis,conjunctivitis, cough,chestorthroattightness, wheezing/bronchospasm, 
dyspnea,anaphylaxis, Arthusreaction,vasculitis, and serumsickness.Nausea, vomiting, diarrhea,
myalgia, arthralgia, headache, fatigue,andhand/foot skinreactionhavealsobeenobserved with
administration ofBC8antibodyandar etherefore similarlyexpectedwithDOTAͲBC8.Inaddition,rapid
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page30of62infusionofDOTAͲBC8mayproducepulmonary, renalorhepatictoxicityasaresultoflysisor
agglutination ofcirculating cells.Table 6describes thegradingofsignificant acutetoxicitiesdueto
DOTAͲBC8infusion.
TABLE6:GradingofAcuteToxicities DuetoDOTAͲBC8 Infusion(fromNCICTCAEversion4.0).
Parameters  1(Mild) 2(Moderate)  3(Severe) 4(LifeͲ
Threatening) 
Immunesystem
disorders: 
AllergicreactionTransient flushingor
rash;drugfever<38°C
(<100.4°F);
intervention not
indicated Intervention indicated; 
respondspromptlyto
treatment Prolonged recurrence of
symptoms; 
hospi[INVESTIGATOR_059] indicated LifeͲthreatening 
consequences; 
urgentintervention 
indicated 

Investigations: 
1.Bilirubin
2.AST
3.Creatinine 
>ULN–1.5×ULN
>ULN–2.5×ULN
>ULN–1.5×ULN
>1.5 ×ULN–3.0×ULN
>2.5 ×ULN–5.0×ULN
>1.5×ULN–3.0×ULN
>3.0×ULN–10.0×ULN
>5.0 ×ULN–20.0×ULN
>3.0
×ULN–6.0×ULN
>10.0×ULN
>20.0×ULN
>6.0 ×ULN
Premedication forand management ofpotentialacutesideeffectsaredescribed undersection[IP_ADDRESS].
Patientsexperiencing acuteallergictypetoxicityduringDOTAͲBC8infusionwillhavetheinfusionslowed
orterminated. Ifgrade2allergictoxicityisencountered, theinfusionshouldbepaused,thepatient
treated asindicatedundersection [IP_ADDRESS],andtheinfusionnotresta rteduntilsymptoms havesubsided. 
Ifgrade3allergictoxicityisencountered anddoesnotresolveusingthemeasures described, theinfusion
must beterminated andnotͲrestarted, and thepatientwillbeoffprotocol.Othergrade2or3acute
toxicitymaybetreatedandtheinfusionresta rted.Iftoxicitypersistsorprogresses, theinfusionwillbe
terminated. Patientswithgrade4acutetoxicitywillhavetheinfusionstoppedandfurtherparticipation 
inthestudywillbeterminated. 
Hepaticand/orrenaltoxicitywillnotbeevidentduringtheDOTAͲBC8infusionbutinsteadwillbe
determined bylaboratory sample sobt ainedattheendofinfusionandthefollowingday. Ifapatient
experiences grade3hepaticorrenaltoxicityafterthefirstdose(associated withthebiodistribution dose
ofradiolabeled DOTAͲBC8),determination ofwhetherornotthepatientcanproceedtothetherapy
dosewillbemadebythePIorhisde signeeinconsultation withtheattending physician, andwilldepend
inpartupontherateofrecoveryfromthelaboratory abnormalities. Apatientexperiencing grade 4
hepatic orrenaltoxicityafterthefirstdosewillnotbeeligibletoreceivethenecessary seconddose
associa t
edwiththetherapydoseofradiolabeled DOTAͲBC8, andwillbetreatedonanalternateprotocol.
14.1.2Toxicityassociated withradiolabeled DOTAͲBC8 
Theriskassociated withtheadministration of~5Ͳ10mCi of111Inisestimated tobelow.Anadverse
eventofgrade4hypotension hasbeenreportedasprobablyrelatedto111Inadministration inone
patientwithBCelllymphoma. Thepatient required2daysofhospi[INVESTIGATOR_059] untilallsideeffectswere
resolved.
Theradioisotope 111Inisarelatively lowͲdoseimagingagentthatiswidelyused inclinicalimaging
applications.111Inisused asatracertofollowbiodistribution andtoestimatetheradiationabsorbed
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page31of62dosefor90Ybasedontheassumption thatbothisotopesbehavesimilarlyinvivowhenstablycomplexed 
byDOTAchelate.90YͲDOTAͲBC8thatdoesnotbindtocellularrecognition sites isexpectedtobecleared
rapi[INVESTIGATOR_375]bythekidneys,resulting inincreased renalexposuretoradiation. Allpatientswillreceive
intravenous hydration before,during,andafter theinfusioninorder tosupportadequate renalfunction
andefficientclearance ofcirculating 90YͲDOTAͲBC8.
Themajor toxicityassociated withtheuseof90YͲlabeled antibodies ismyelosuppression. Thiseffectis
partlyduetodissociation of90YfromtheDOTAmoleculeandsubsequent accumulation offree90Ymetal
ioninbonethatirradiates thebonemarrow.Thedegreeofmyelosuppression isafunction ofresidence 
time intheblood,chelatestability,andtheamountof90Yadministered.In addition,DOTAligand
complexes ofM+3metals,includingyttrium,areknowntobekinetically inert;therefore, releaseoffree
metal isexpectedtobeminimal.Patients willundergofurtherintendedmyelosuppression from
treatment withFLUandTBIpriortoHCT.
Inpreviousstudiesusinghighdosesoftargetedradiationdelivered via131IͲBC8inanallogeneic 
transplant settingforleukemiaand myelodysplastic syndrome, significant pulmonary toxicitiesthat
wereconsidered atleastpossiblyrelatedtothestudydrugoccurredwithinthefirst100dayspostͲ
transplant in7ofthefirst74patientstreated(9%). These eventsincludedyspneaand hypoxiaatNCI
CTC/CTCAE Grade3and above,bronchiolitis obliterans organizing pneumonia (BOOP),and
pneumonitis/ pulmonary infiltrates. In
thesame patientpopulation, 16of34(47%)patientssurviving
morethan100dayspostͲtransplant hadlaterreportsofpulmonary eventsduringfollowͲup.Mostof
theseweremild(e.g.,cough),but4patientsshowed radiographic changessuggestiveofpneumonitis 
and/orfibrosis.
Additional radiationͲ
related toxicitiesmayincludedamage tovariousorganssuch astheskin,lungs,liver
orkidney.Radiation exposure isalsoassociated withariskofsecondary malignancy. Thereisararerisk
ofvenoͲocclusive disease (VOD),which causesabnormal liverfunction,bodyswellingfromwater
retention andpainintheright sideoftheabdomen. Patien tswillbeinforme
daboutthese potentially 
fatal risks.
14.2Fludarabine 
14.2.1Description 
Fludarabine monophosphate isapurineantimetabolite that,after administration, undergoes rapid
conversion inplasmatothenucleoside 2ͲfluoroaraͲA(FͲaraA).FͲaraAsubsequently enterscellswhereit
isphosphorylated toFͲaraATPand themonophosphate FͲaraAMP. Onceactivated, FͲaraATPinhibits
DNApolymerase andribonucleotide reductase. Themonophosphate FͲaraAMP, onceincorp oratedinto
DNA,isaneffective
DNAchain terminator. Following IVadministration, thedrugismetabolized to2ͲFͲ
araAand widelydistributed intissues. 2ͲFͲaraAisexcretedprimarilyinurine andhasaterminal
elimination halfͲlifeof7Ͳ12hr.
14.2.2Storageandadmini strati on
Fludarabine monophosphate iscommercially availableasa50mg/vialwhichisreconstituted with2ml
ofsterile water,resultingina25mg/ml solution.Thedesireddoseisfurtherdilutedtoconcentrations of
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page32of620.04Ͳ1mg/mlinnormalsalineor5%dextrose(50Ͳ100ml)forinjectionandadministered byIVinfusion.
Fludarabine willbeadministered byIVinfusionover 30minutesinadoseof30mg/m2/day ondaysͲ4to
Ͳ2.
14.2.3Sideeffectsandtoxicity
Clinicaltoxicitiesoffludarabine monophosphate include:myelosuppression, primarilylymphopenia and
granulocytopenia, alopecia,rash, dermatitis, nausea,vomiting, anorexia, stomatitis, diarrhea,
somnolence, fatigue,peripheral neuropathy, mentalstatuschanges,corticalblindness, hepatocellular 
toxicitywithelevation inserumtransaminases, andinterstitial pneumonitis. Theseeffects arereversible 
whenthedrugisdiscontinued. Immunosuppression observed withtheuseoffludarabine increases the
riskofinfecti o
nwhich canbelifeͲthreatening. 
14.3Cyclosporine (CSP)
SeeSCCA standardpracticemanual forinformation aboutadministration, toxicityandcomplications. 
14.4Mycophenolic AcidMofetil(MMF)
14.4.1Description 
MMFisthemorpholinylethylester prodrugoftheactiveimmunosuppressant mycophenolic acid(MPA).
Thisactivemetabolite isanoncompetitive, reversible inhibitorofinosinemonophosphate 
dehydrogenase, particularly thetype IIisoform thatismoreprominent inactivated lymphocytes. Asa
resultoftheinhibition ofdenovopurinesynthesis, proliferation ofTͲandBͲlymphocytes isblockedan d
antibodyproduction isinhibited. Therearenopharmacokinetic interactions withganciclovir, 
cotrimoxazole, oralcontraceptives orcyclosporine. 
14.4.2Storageandadministration
MMFiscommercially availableinanoraland anintravenous formulation. Theoralformulation is
suppliedin250mghardgelatin capsulesand canbestoredatroomtemperature. MMFfori.v.
administratio
nissuppliedasalyophilized powder inaglassvialcontaining theequivalent of500mg.
14.4.3Sideeffectsandtoxicity
Sideeffectprofilesincludediarrhea,leukopenia, sepsis,allergicreactions, and vomiting. MMFuse
duringpregnancy carries asignificant riskofmiscarriage orbirthdefects.Anincreaseince rtaintypesof
infectionmainlyfromtheherpesvirusfamily(CMV,HSV&VZV)andcandidahasbeenreported. There
havebeenreports ofprogressive multifocal leukoencephalopathy (PML),sometimes fatal,andofPure
Red CellAplasia(PRCA)inpatientsreceivingMMFaspartofanimmunosuppressive regime n .MMFhas
notbeenstudiedextensively inpatients after HCT.Mostcommonsideeffects knownfromstudiesin
patientswithsolidorgantransplants arehematologic (declineinWBC and hematocrit) and
gastrointestinal (nausea,vomiting, diarrhea,G.I.bleeding). Experience hasshown thatnauseacanbe
successfully treatedwithantiͲemetics,andtha tsideeffectsoftenrespond toadecreaseindose.Several
etiologicfactorsmaycausealterations inG.I.and hematologic parameters inthesettingofHCT.MMF
doseadjustments willtherefore bemadewhenclinicallyindicated iftheresponsible physician ruled out
otherpossiblecauses.Doseadjustments shouldbediscussed withtheprincipalinvestigator. Withthe
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page33of62exception ofhypophosphatemia thereseems tobenodifference insideeffects betweeni.v.and oral
MMFadministration andefficacyisthesamewithbothadministration routes.
15.0ADVERSE EVENTREPORTING 
15.1AdverseEventDefinitions 
xAdverseEvent
AnAdverseEvent(AE)isanyuntoward medicaloccurrence inaclinicalinvestigation subject
administered amedicinal product;theeventdoesnotnecessarily haveacausalrelationship with
studydrugadministration orusage. Anadverseeventcantherefore beanyunfavorable and
unintended sign(including anabnormal laboratory finding),symptom, ordiseasetemporally 
associated withtheuseofamedi cinalp
roduct,whetherornotconsidered relatedtothemedicinal 
product.
xSeriousAdverse Event
Aseriousadverseevent(SAE)isdefinedasanuntoward medical occurrence thatresultsinanyof
thefollowing outcomes: 
oDeath.
oLifeͲthreatening situation(i.e.,withanimmedia t eriskofdeath fromtheeventasitoccurredbut
notincludinganeventthat, haditoccurredinamoreseriousform, mighthavecaused death).
oInͲpatient hospi[INVESTIGATOR_059] orprolongation ofexistinghospi[INVESTIGATOR_059]. Inpatient hospi[INVESTIGATOR_059] 
comprises formal admission toahospi[INVESTIGATOR_307]formedical reasons, foranylengthoftime,whetheror
nothospi[INVESTIGATOR_059] extendsovernight. However, hospi[INVESTIGATOR_307]admissio nsfor
administration ofthe
studydrug,procedures requiredbythestudyprotocol,ortumorͲrelateddiagnostic procedures 
arenotconsidered serious.
oPersistent orsignificant disability/incapacity orsubstantial disruption oftheabilitytoconduct
normallifefunctions. 
oCongenital anom al y/birthdefect.
oAnimportant medicaleventthatrequiresintervention topreventoneoftheaboveoutcomes.
xUnexpected AdverseEvent
Anunexpected adverseeventisdefinedasaneventthathasanatureorseverity,orfrequency that
isnotconsistent withtheapplicable investigator brochure.“Unexpected,” asused inthisdefinition,
referstoanadv
ersedrugexperience that hasnotbeenpreviously observed andreportedrather
thananexperience that hasnotbeenanticipated basedonthepharmacological properties ofthe
studydrug.

15.2Monitoring andRecording AEs
Adverseeventswillbeassessedbytheinvestigator orqualifieddesignee anddesigneeand recordedin
theCRFs.Theinvestigator shouldattempttoestablishadiagnosis oftheeventonthebasisofsigns,
symptoms and/orotherclinicalinformation. Insuchcases,thediagnosis shouldbedocumented asthe
adverseeventand/orseriousadverseeventandnotdescribed as theindividual signsorsymptoms. The
following information shouldberecorded: 
xDescription oftheadverseeventusingconcisemedicalterminology 
xDescription astowhetherornottheadverseeventisserious
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page34of62xThestartdate(date ofadverseeventonset)
xThestopdate(dateofadverseeventresolution) 
xTheseverity (grade) oftheadverseevent
xAdescription ofthepotentialrelatedness oftheadverseeventtostudydrugorastudyprocedure 
xTheactiontakenduetotheadverseevent
xTheoutcomeoftheadverseevent.

15.3GradingoftheSeverityofanAdverse Event AEswillbegradedinseverity according totheNCI
Common Terminology CriteriaforAdverseEvents(CTCAE)Version 4.0
(http://evs.nci.nih.gov/ftp1/CTCAE/About.html). IfaCTCAEcriteriondoesnotexist,theinvestigator
shouldusethegradeoradjectives: Grade1(mild),Grade2(moderate), Grade3(severe),Grade 4(lifeͲ
threatening), orGrade5(fatal)todescri bethemaxi mumin tensity oftheadverseevent.However, the
BearmanScaleofRegimenͲRelated Toxicitywillbeused fordecisions regarding doseescalation/ deͲ
escalation andinvocation ofstoppi[INVESTIGATOR_007]rules.

15.4Attribution ofAdverseEvent Association orrelatedness tothestudyagentwillbeassessedby
theinvestigator asfollows:
•Definite:Theeventfollowsareasonable temporal sequence fromexposuretotheinvestigational 
agent,hasbeenpreviously described inassociation withtheinvestigational agent,andcannot
reasonably beattributed tootherfactorssuchasthepatie nt’sclinicalstate,other therapeutic 
interventions orconcomitant medications; AND theeventdisappears orimproves withwithdrawal 
oftheinvestigational agentand/orreͲappearsonreͲexposure (e.g.,intheeventofaninfusion
reaction). 
•Probable:The eventfollowsareasonable temporalsequence fromexposure totheinvestigational 
agentandhasbeenprevio uslybee ndescribed inassociation withtheinvestigational agentOR
cannot reasonably beattributed toother factorssuchasthepatient’sclinicalstate, other
therapeutic interventions orconcomitant medications.
•Possible:Theeventfollowsareasonable temporal sequence fromexposure totheinvestigational 
agent,butcouldbeattributable toother factorssuchasthepatient’sclinic alstate, other
therapeutic interventions orconcomitant medications.
•Unlikely:Toxicityisdoubtfully relatedtotheinvestigational agent(s).Theeventmaybeattributable 
tootherfactorssuchasthepatient’sclinicalstate, other therapeutic interventions orconcomitant 
medications. 
•Unrelated: Theeventisclearlyrelatedtootherfactorssuchasthepatie nt’sclinicalstate, other
therapeutic interventions orconcomitant medications.

ForgeneralAEassessment, anAEisconsidered relatedifitisassessedasdefinitely, probably, or
possiblyrelated; unrelated ifitisassessedasunlikelyrelatedorunrelated. Fordetermination ofIND
safetyreporting, AEattribution willbeassessedaccording tothesuspected adversereactiondefinition 
described in21CRF312.3
2asanAEforwhich thereisareasonable possibility thatthedrugcausedthe
adverseeventwhere“reasonable possibility” meansthereisevidencetosuggestacausalrelationship 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page35of62betweenthedrugandtheAE.Suspected adversereactions thatarebothseriousandunrelated willbe
reportedtotheFDAasanINDsafetyreport,inaccordance withregulations under21CFR312.32.

15.5AdverseEventReporting Period
AEswillbemonitored andrecordedinstudyͲspecificcasereportforms(CRFs).Fromthetime offirst
exposure toaninvestigational agent(i.e.,thestartofthe111InͲDOTAͲBC8infusion)throughday+100
postͲtransplant orthroughdischarge priortothat datefromtheSCCA systemtocareofthepatient’s
primary physician, nonͲ hematologic adverseeventsofшgrade3,possiblyrelatedeventsofgrade2that
havenotpreviously beenobserved withcomponents ofthestudyregimen, andallseriousadve rse
eventswillbecapturedinprotocolͲspecific casereportforms.Gradeч4hematologic toxicityisexpected
andwillonlyberecordedastimetoengraftment. Beyondday+100, disease progression, development 
ofsecondary malignancies, andsurvivalonlywillbecollected. AEswithanonsetdatepriortothefirst
exposure toaninvestigatio nalproductwillnotberecorded,
exceptinthecaseofclinicallysignificant
worsening oftheAEduringthespecifiedmonitoring timeframe.Asubjectwithdrawn fromthestudy
becauseofanadverseeventmustbefolloweduntiltheclinicaloutcomefromtheadverseeven tis
determ
ined.

Thefollowing eventsarenotidentified asAEsinthisstudy:
xDiseaseprogression orrelapse.However, clinicaleventsassociated withprogression/relapse may
bereportable asAEs.
xHospi[INVESTIGATOR_059] forthepurposeoffacilitating conditioning and/orstemcellinfusionisnot
considered anAE.AnyAErequiringprolongation ofthishospi[INVESTIGATOR_059] willbereco rdedandsubject
toapplicable SAEreporting. 
xMedicalorsurgicalprocedures inandofthemselves, includingthosethat require hospi[INVESTIGATOR_059] 
(e.g.,surgery,endoscopy, biopsyprocedures) arenotconsidered AEs.However, aneventor
condition requiringsuchprocedures maybeanAE.

15.6AdverseEventReporting Requirements 
15.6.1Research SiteReporting Requirements 
Classification ofaneventasseriousornonͲserious(seeSection15.1)determines thereporting 
procedures tobefollowedbythesiteforreporting theeventtotheINDSponsor.Theinvestigator must
reporteventstotheFredHutchIRBinaccordance withthepoliciesoftheIRB.

TABLE7:PItoINDSponsorReporting R
equirements forAdverseEvents
Classification  Reporting Time Reporting Action ContactInformation 
Serious
Adverse
Event(SAE)FatalorlifeͲ
threatening Within24hoursofresearch
teamawareness Email notification toIND
Sponsor’s MedicalMonitor&
ISIOCAdministrator MedicalMonitoremail:
[EMAIL_2231] 
ISIOCemail:
[EMAIL_2232] 
AllSAEsWithin2business daysof
researchteamawareness Submitcompleted 
Institution ͲSponsored IND
SAEReporting Formsigned
byPIordesignated subͲISIOCFax:
206Ͳ667Ͳ6068
ISIOCemail:
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page36of62Investigator  [EMAIL_2232] 
NonͲseriousAdverseEventPerCRFcompletion 
guidelines Recordinformation on
appropriate CRFsN/A
*Research teamisdefinedastheindividuals listedonthedelegation ofauthority log.Physicians listedonthestudy’sdelegation 
ofauthority logastransplant serviceattending physicians delegated authority toadminister informed consentwillnotbe
considered partoftheresearchteamunlessadditional responsibilities related totheconductofthestudyhavebee ndelegated 
tothembythePrincipalInvestigator. 
Theinformation intheInstitution ͲSponsored INDSAEReporting Form mustmatchorbereconciled with
theinformation recordedintheadverseeventssectionoftheCRFandstudydatabase. Forexample,the
same adverseeventtermshouldbeused onbothforms.
Theinvestigator mustreporteventstotheFredHutchIRBinacco rdance withthepoliciesoftheIRB.The
INDsponsorassumesresponsibility forINDsafetyreporting totheFDAandparticipating investigators, in
accordance withregulations under21CFR312.32.
15.6.2FredHutchINDSponsor Reporting Requirements 
Thesponsorassumesresponsibility forINDsafetyreporting totheFDAandparticipating investigators, in
accordance withregulati onsunder21CFR312.32.
Eachseriousadverseeventreportreceivedfromtheinvestigator
willbeevaluated bytheMedical
Monitorwhowillassess theseriousness oftheevent(seeSection 15.1),theexpectedness oftheevent
(seeSection 15.1),andtherelationship toparticipation inthestudy(seeSecti on15.4).Forregulatory
reporting purposes, theINDSponsorwilldetermine expectedness relatingtotheinvestigational product
usingsafetyinformation specifiedintheInvestigator Brochure. Aneventwillbeclassifiedasrelatedif
eithertheinvestigator ortheINDSponsordetermines thattheeventmayberelatedtothestudydrug.

TheINDSponsor
oritsdesigneewillprovide allinvestigators withasafetyletternotifyingthem ofan
eventthatmeetsFDAINDSafetyReporting criteria.Investigators willberequested toprovide written
notification ofsafetyreporttotheFredHutch IRBassoon asispractical,consistent wit hIRB
requirements. 
15.7SAESAssociated withHematopoietic CellTransplantation (HCT)
Certaineventsthatarecommonly observed asSAEsfollowing HCTaredescribed inAppendix Einorder
tofacilitateassessments ofattribution. SAEsthatareidentified asroutinelyexperienced inthe
allogeneic transplant settingwouldtypi[INVESTIGATOR_897]beassessedasunrelated toelements oftheinvestigational 
regimenusedinthisprotocol.Symptoms associated withGvHDaredescribe dunderAppe ndicesBan d
C.
16.0DOSEESCALATION 
16.1Dose toNormalOrgan
Doseescalation willbeconducted bythe“twoͲstage”approach introduced byStorer.79TheMTDwillbe
definedasthedosethatisassociated withatrueDLTrate of25%.ADLTwillbedefinedasaGradeIII/IV
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page37of62regimenͲrelatedtoxicity(Bearman scale)occurring within30dayspostͲtransplant. Patients ateither
stageareconsidered evaluable after survivalof30dayspostͲtransplant, orearlier ifGradeIII/IV
regimenͲrelatedtoxicity(RRT)occursbeforethattime.
Inthisstudyaninitialconservative 90Ystartingdosehasbeenselectedtodeliveranestimated 6Gyto
thenormalorganthatreceivesthehighestdose.Thisstartingdoseisbasedondatathat utilized90YͲ
ibritumomab tiuxetan (Zevalin®)antiͲCD20RITaspartofahighͲdosetherapyregimeninthesettingof
autologous HCTfornonͲHodgkin lymphoma (NHL).These groupshaveshown thatemploying standard
(0.4mCi/kg)dosesof90YͲibritumomab tiuxetanbasedapproach aspartofaHCTregimenisfeasible,
efficacious and safe, withoutanegativeimpactonengraftment.80Ͳ81Additional investigators have
explored theuseofescalating dosesof90YͲibritumomab tiuxetanincombination withhighͲdose
chemotherapy and autologous HCTforNHL.82Ͳ86These studieshavesafelydelivered ш0.5mCi/kg with
dosesestimated todeliver>15Gytocritical organs(liverinmostcases)whencombined withhighͲdose
chemotherapy andautologous HCT.Inaddition,theestimated MTDofradiationdelivered tothenormal
organreceivingthehighestdoseof131IͲBC8AbonourPhaseIstudy(Protocol#1432)was 24Gy
delivered totheliver.Giventhedifferences inradionuclides utilizedbetweenProtocol#1432 and this
study,combined withpriorexperiences using90YͲibritumomab tiuxetan,weanticipate thatadoseof6
Gydelivered by90YͲDOTAͲBC8willrepresent aconservative startingpointresultinginlesstoxicitythan
hasbeenobserved using 24Gydelivered by131IͲBC8Aborusing higherdosesof90Yasreportedbyother
groups.
Singlepatientswillbeenteredonthefirststage, and escalation by2Gyincrements (intheradiation
dosedelivered tothenormal organreceivingthehighestdose;seeTable4)willoccuruntilapatient
experiences aGradeIII/IVregimenͲrelatedtoxicity(Bearman scale)orDLT,atwhichpointthesecond
stagewillbegin
atthenext lower doselevel.Ifthefirstpatient(i.e.,atthestartingdoselevel)hasDLT,
deͲescalation willoccurby2Gyincrements untilthefirstdoseatwhichapatient doesnothaveDLT,at
whichpoint thesecondstagewillbeginatthat doselevel.
Inthesecondstage, patientswillbeenteredincohortsof4evaluable patients.Ifthecurrentcohortis
treatedatdose levelk,thenext cohortwillbetreatedaccording tothefollowing: levelkͲ1if2DLT’sare
encountered among the4orfewerpatientsintheco
hort;levelkif1DLTisobserved withinthecurrent
cohort;levelk+1if0DLT’sareseeninthecurrentcohort. Theserulesarefolloweduntilaminimum of
20evaluable patientshavebeentreatedatthesecondstageandhavebeenevaluatedfor DLTsthrough
day100following transplant. Itispossiblethatapatient willbeenteredontheprotocol beforea
patientcurrentlyenrolledonStage 1orall4patientsinacohort inStage2havebeenfollowed
sufficiently longtoevaluate toxicity(30dayspostͲtransplant). Suchpatientswillbetrea tedatthe
currentdoselevelandwillbeused forpurposesoffittingthedoseͲresponse curveuponcompletion of
thesecondstage.However, thesepatientswillnotbeusedforpurposesofdosemodification unless
requiredintheinterestsofpatientsafetybasedontheclinicaljudgmen toftheprincipalinvestigator, 
norwillthey becountedtowardstherequirednumberofpatientsforcompletion ofthesecondstage.
Following thecompleted observation ofthefinalpatient,atwoͲparameter logisticmodelwillbefitto
thedata,therebygenerating adoseͲresponse curvebasedontheobserved toxicityrateatthevarious
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page38of62doselevelsvisited.Basedonthisfittedmodel,theMTDisestimated tobethedosethatisassociated 
withatoxicityrate of25%.
16.2Dose toBoneMarrow andGraftFailure
Initiallynopatientwillreceiveadoseof90Yestimated todelivermorethan43Gytothemarrow(5Gy
lessthanthe48Gyfrom131IͲBC8Abtolerated onProtocol#1432).Patientsforwhomtheamountof90Y
requiredtodeliverthestipulated dosetoliverwouldresultinthedelivery ofmorethan 43Gyto
marrowwillhavethe90Ydoselimitedtotheamountwhich woulddeliver43Gytomarrow.If0of3,or
nomorethan1of6patientstreatedatthisestimated dosetomarrowexperiences graftfailure,wewill
then escalateinincrements of5Gytomarrowinthose patientsasallowedbythemarrow:liver 
radiationabsorbed doseratio(i.e.,without exceeding intendedestimate d
radiationabsorbed doseto
liver).TheMTDofradiationdosetomarrow willbeestimated tobethedosebelowanydosewhere>2
patientsofupto6treatedexperience graftfailure.
16.3Dose LimitstoOtherNormalOrgans
AlthoughtheRITapproach isintendedtodelivermyeloablative dosesofabsorbed radiationtositesof
disease,itwillbeimportant toensurepatientsafetyandminimizetheriskofradiation toxicityinnormal
organs.In thisstudythetotal radiationdosewillbelimitedtoensurethatcriticalorgansreceive
radiationabsorbed dosesbelowknowntolerance limits.Thetotaldoseincludescontributions fromboth
externalandinternalradiationsources.Theinter
nalradiationcomponent istheabsorbed doseto
normalorgansfrom90YͲDOTAͲBC8.Theexternalradiationdose inthisstudyis200cGyofTBI.For
patientswhohavepreviously beentreatedwithexternalbeamradiotherapy, thepriorradiationdose
delivered willalsobefactoredintodetermination ofthemaximum radiationdosepermitted forthat
individual. Althoughthere areseveralpublished standards forthetoler ance limitsforradiation
absorbed dosesforcriticalnormalorgans, themostwidelyquotedarethose established byEmamietal.
forhighdoserate,externalgammaradiationtherapy delivered byalinearaccelerator.87While the
Emamietal.valuesmaynotdirectly equatetotolerance limitsforradiationabsorbed dosestocritical
normalorgansdelivered byverylowdoserate internal radiationtherapyusingbetaͲparticleemitting
radionuclides, wewilladoptthem asaconservative approach topatient safety.Table8showsthe
functional doselimitstha twewillfollow.

TABLE8:Functional DoseLimitstoNormalOrgans
OrganaMaximum wholeorganTD
5/5limit(cGy)87Radiation tobe
delivered viaTBI
(cGy)Maximum radiation dose
permissible fromYͲ90(cGy)
Kidneys 2300 200 2100
Bladderwall 6500 200 6300
Brain 4500 200 4300b
Heart 4000 200 3800
Stomach 5000 200 4800
Smallintestine 4000 200 3800
Upperlargeintestine 4500 200 4300
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page39of62OrganaMaximum wholeorganTD
5/5limit(cGy)87Radiation tobe
delivered viaTBI
(cGy)Maximum radiation dose
permissible fromYͲ90(cGy)
Lowerlargeintestine 6000 200 5800
Liver 3000 200 2800c
aLungsarenotaccessible and arenotmeasured usingstandarddosimetric methodsduetorib
attenuation. 
bMaximum YͲ90radiationdosetobraininpatients withpriorevidenceofCNSleukemicinvolvement 
maybefurther decreased basedonanticipated externalcranialorcranialͲspi[INVESTIGATOR_1304]irradiation asdescribed 
undersection10.10.
cActualdosetoliverisexpectedtobelower, reflecting doseescalation schemadescribed under section
16.1.
16.4Additional ClinicalDose LimitsandModifications 
Insome patients,theamountof90Yrequiredtodeliverthetargetdosetonormalorgan,asdetermined 
bybiodistribution studies,maybedeemedclinicallyinappropriate bytheinvestigator (e.g.,ifthe
amountof90Yactivity(mCi)issignificantly higherthanhasbeenpreviously delivered inaclinicalor
researchsetting).Inthisevent, thepatientmaybetreatedatalowerdosebasedonuseofapriordose
leveloruseofanalternatedosedetermination mechanism, suchasmCi/kg ormCi/m2,atthediscretion 
oftheinvestigator inconjunction withtheattending physician andaNuclear Medicine representative.
17.0STATISTICAL CONSIDERATIONS 
Theprimaryobjective ofthisstudyistoestimatetheMTDof90YͲDOTAͲBC8whencombined witha
reducedintensityconditioning regimen.TheMTDwillbedefinedasthedoseof90YͲDOTAͲBC8used in
combination withthereducedͲintensityHCTconditioning regimenthatisassociated withaGradeIII/IV
RRTortrue DLTrate of25%.Inthisprotocol forpatientswithadvanced AML,ALL,orhighͲriskMDS,the
doseadjustment schemaisdesignedtotargeta25%rate ofGradeIII/IVRRTsincethesepatientsareat
suchhi
ghͲriskofrelapsepostͲtransplant and couldbenefitfromthedelivery ofmaximum radiation
dosestoleukemiccellsinBMand spleen.DetailsofthedoseͲmodification algorithm arecontained in
section 16.1.
Asecondary objectiveofthisstudyistodetermine ifengraftment canbeachievedsafelyamong
patientswithhighͲ
riskhematologic malignancies whoundergoHCTusingDOTAͲBC8RIT.Although we
havenotseenrejectioninanyofourpriorradiolabeled BC8Abstudies,inthisprotocolifsufficient 
evidenceexistssuggesting thatthetrue rate ofgraftrejectionexceeds 20%,theprotocol willbe
suspended andreviewed bytheinvestigators and other experts/committees asappropriate to
determine whetherthetrialshouldbeterminated, continued withoutchange,orcontinued with
revisions. Sufficient evidencewillbetakentobealower limitoftheappropriate 80%oneͲsided 
confidence intervalassociated withtheestimated proportion ofrejections inexcessof0.20.These
proportions and associated confidence intervalswillbecalculated afterevery5thpatientenrolled is
evaluable.Operationally, graftrejectionatanyofthefollowing observed proportions wouldtriggera
suspension: 3/5,4/10,5/15, 6/20,8/25,9/30,10/35,or11/40.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page40of62Inadditiontograftrejection, thestudywillbesuspended ifthereissufficient evidencetosuggestthat
thetruerateofgradesIIIͲIVacuteGvHDatday+100 isexcessive (gradedaccording totheestablished 
criteria attheFHCRC).Sufficient evidenceforgradesIIIͲIVGvHDwillbetakentobeanobserved 
proportion ofGvHDwhose lower limittotheassociated oneͲsided 80%confidence intervalexceeds
35%.Aswithrejection, theseproportions willbeevaluated afterevery5thenrolledpatientbecomes
evaluable. Operationally, anyofthefollowing observed proportions ofGvHDwouldleadtostudy
suspension: 4/5,6/10,8/15, 10/20,12/25,14/30,16/35,or18/40.
Eachsuspension rulewillbeevaluated among allpatientsenrolled,regardless ofthedoseof90YͲDOTAͲ
BC8administered. 
Table9summarizes theoperating characteristics ofeach oftheserules,each ruleconsidered
independent oftheother.

TABLE9:Characteristics ofSuspension Rules
Numberof
patientsTruerateof
graftrejectionProbability of
suspension1Truerateof
GVHDProbability of
suspension2
20 .15 .12 .25 .04
35 .15 .13 .25 .05
20 .35 .80 .50 .66
35 .35 .90 .50 .83
1Represents estimateoftheprobability ofstudysuspension byassociated numberofpatientsdueto
excessgraftrejection. 
2Represents estimateoftheprobability ofstudysuspension byassociated numberofpatientsdueto
excessGvHD.
Eachestimated from5,000MonteCarlosimulations. 
BecausetheantiͲleukemic effectof90YͲDOTAͲBC8combined withthisreducedͲintensityregimenis
unknown, butlikelytoincreaseathigherdoselevels,wewillfollowdisease responseand durationof
remission, butrates ofrelapsepostͲtransplant, orfailuretoenterremission, willnothaltthestudy.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page41of6218.0TARGETED/PLANNED ENROLLMENT
EthnicCategory Sex/Gender 
 Females Males Total
HispanicorLatino 1 1 2
NotHispanicorLatino 13 15 28
EthnicCategoryTotalofAllSubjects*  14 16 30
RacialCategories 
American Indian/Alaska Native 0 1 1
Asian 1 1 2
NativeHawaiian orOtherPacificIslander 1 1 2
BlackorAfricanAmerican  1 1 2
White 11 12 23
TotalofAllSubjects 14 16 30
19.0TERMINATION OFSTUDY
Individual patientsmaychoosetodiscontinue treatment atanytime.Treatment mayalsobeterminated 
atthediscretion ofthePrincipalInvestigator ifcontinuation oftreatment isdeemedtopose
unacceptable toxicitytothepatient.Specificreasonsforwithdrawal mayinclude:
a. Patientrequest.
b. Unacceptable toxicityduringdosimetry antibodyinfusion(seesections14.0,4.3,and 17.0for
complete toxicitydescri pti
onsandstoppi[INVESTIGATOR_007]rules).
c. Development ofantiͲmouse antibodies. 
ThePIandINDsponsormayterminate thestudyatanytime. TheIRBandFDAalsohavetheauthority to
terminate thestudyshoulditbedeemednecessary. Stoppi[INVESTIGATOR_007] rules associated withlackofefficacyand
excessive toxicityaredetail
edinthestatistical section.
20.0DATAANDSAFETY MONITORING PLAN
Thisisasingleinstitution trialwhereallpatientsarefollowedcloselybytheinvestigators. Additionally, 
thetrial designprovidesrules fordoseescalation depending upontherateofdevelopment ofGrade
III/IVRRT(Bearman Scale).Thisdesign mandates ongoingreviewoftheoutcomeofpreviouspatients
treatedonstudysothattheappropria teDoseLevelforthecurrentpa tient canbeassigned. The
principalinvestigator, primaryresearchnurse,andstudydatacoordinator communicate routinely
(typi[INVESTIGATOR_897]weekly) toreviewrecentlyacquireddata,stoppi[INVESTIGATOR_007]rules,andadverseevents.Thedata
recordedwithintheresearchchartsandprotocol database iscompared withtheactualdatathatis
availablefromthemedi ca
lrecordand/orclinicalhistories.Data detailedintheresearchcasereport
formsincludesthenature andseverityofallsignificant toxicities, whicharealsoreportedasdescribed 
above.Allinvestigators ontheprotocol havereceivedformaltraining intheethical conductofhuman
research. 
Institutional supportoftria
lmonitoring willbeinaccordance withtheFHCRC/University ofWashington 
Cancer Consortium Institutional DataandSafetyMonitoring Plan(DSMP).Undertheprovisions ofthis
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page42of62plan,FHCRCClinicalResearchSupportcoordinates dataandcompliance monitoring conducted by
consultants, contractresearchorganizations, orFHCRCemployees unaffiliated withtheconduct ofthe
study. Independent monitoring visitsoccuratspecified intervalsdetermined bytheassessedrisklevel
ofthestudyandthefindingsofpreviousvisitspertheinstitutional DSMP.

Inaddition,protocols arereviewed atleastannuallyandasneededbytheConsortium DataandSafety
Monitoring C
ommittee (DSMC),FHCRCScientificReviewCommittee (SRC)andtheFHCRC/University of
Washington Cancer Consortium Institutional ReviewBoard(IRB).Thereviewcommittees evaluate
accrual,adverseevents, stoppi[INVESTIGATOR_007]rules,andadherence totheappli cabledataandsafetymoni toringplan
for
studiesactivelyenrollingortreatingpatients.TheIRBreviewsthestudyprogressandsafety
information toassess continued acceptability oftheriskͲbenefitratioforhumansubjects.Approval of
committees asapplicable isnecessary tocontinuethestudy.
Thetrial willcomplywiththestandard guidelines setforthbytheseregula tory committees andother
institutional, stateandfederalguidelines. 
21.0DATAMANAGEMENT/CONFIDENTIALITY 
Theinvestigator willensurethat datacollectedconformtoallestablished guidelines. Eachsubjectis
assignedauniquesubjectnumbertoassuresubject confidentiality. Subjectswillnotbereferredtoby
thisnumber,byname, orbyanyother individual identifierinanypublication orexternalpresentation. 
Thelicensedmedicalrecordsdepartme nt,affiliate dwiththeinsti tutionwherethesubjectreceives
medicalcare,maintains alloriginal inpatientandoutpatient chartdocuments. Additional clinicaldata
maybemadeavailablefromtheFredHutchcoredatabase(Gateway), which ismanaged andverified
independent oftheresearchgroup.
TheresearchteamwillmaintainCaseReportForms(CRF)andassociated researchdocume nta tionfor
each patienttreatedundertheprotocol.Thisdocumentation includesbothclinicaldataandstudyͲ
specificdocuments foreachpatient.Additional studyͲspecificdocuments andradiologic dataare
maintained bytheUWDivisionofNuclearMedicine.The PrincipalInvestigator oradesigneewillverify
completed CRFsagainstsourcedocumentation onanongoingbasisas they arecompleted forindividual 
patients.CRFsshouldbecomplete anddataenteredintothestudy databasewithin120daysof
transplant. Datarequiredforanalysisofpatientstreatedonthisprotocol willbemaintained ina
password Ͳprotected studyͲspecific database. DatafromtheCRFsarekeyeddire ctlyintothedatabaseby
authorized researchstaffandverifiedonanongoingbasis.
22.0REFERENCES 
1.PagelJM,Appelbaum FR,EaryJF,etal. 131IͲantiͲCD45 antibodyplusbusulfanand
cyclophosphamide beforeallogeneic hematopoietic cell transplantation fortreatment ofacute
myeloidleukemiainfirstremission. Blood .2006;107(5):2184 Ͳ2191.
2.PagelJ,GooleyT,Rajendran J,etal.TargetedRadiotherapy Using131IͲantiͲCD45 AntibodyFollowed
ByAllogeneic Hematopoietic CellTrans
plantation (HCT):TheRelationships AmongDosimetry, Bone
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page43of62MarrowUptake, and Relapse. European JournalofNuclearMedicineandMolecular Imaging .
2006;33(Supp 2):S193.
3.Redwood WR,TomTD,StrandM.Specificity, efficacy,and toxicityofradioimmunotherapy in
erythroleukemic mice. CancerRes.1984;44(12 Pt1):5681Ͳ5687.
4.MacklisRM,KaplanWD, FerraraJL,Kinsey BM,KassisAI,BurakoffSJ.Biodistribution studiesofantiͲ
Thy1.2IgMimmunoconjugates: impli c
ationsforradioimmunotherapy. IntJRadiat Oncol BiolPhys .
1988;15(2):383 Ͳ389.
5.BadgerCC,KrohnKA,ShulmanH,FlournoyN,Bernstein ID.Experimental radioimmunotherapy of
murinelymphoma with131IͲlabeledantiͲTͲcellantibodies. CancerRes.1986;46(12 Pt1):6223Ͳ6228.
6.KnoxSJ,LevyR,MillerRA,etal.Determinants oftheantitumoreffectofradiolabeled mo noclonal
antibodies. CancerRes.1990;50(16):4935 Ͳ4940.
7.NourigatC,BadgerCC,Bernstein ID.Treatment oflymphoma withradiolabeled antibody: 
elimination oftumorcellslackingtargetantigen.JNatlCancerInst.1990;82(1):47 Ͳ50.
8.Matthews DC,Appelbaum FR,EaryJF,etal.Radiolabeled antiͲCD45 monoclonal antibodies target
lymphohematopoietic tissueinthemacaque. Blood .1991;78(7):1864 Ͳ1874.
9.Schmidberger H,Buchsbaum DJ,Blazar BR,EversonP,ValleraDA.Radiotherapy inmicewith
yttriumͲ90ͲlabeledantiͲLy1monoclonal antibody: therapyoftheTcelllymphoma EL4.CancerRes.
1991;51(7):1883 Ͳ1890.
10.Matthews DC
,Appelbaum FR,EaryJF,etal.Radiolabeled antiͲCD45 monoclonal antibodies target
lymphohematopoietic tissueinthemacaque. BoneMarrow Transplant .1992;10(Suppl 1):77Ͳ81.
11.vanderJagtRH,BadgerCC,Appelbaum FR,etal.Localization ofradiolabeled antimyeloid antibodies 
inahumanacuteleukemiaxenograft tumor model.CancerRes .1992;52(1):89 Ͳ94.
12.Buchsbaum DJ,WahlRL,Normolle DP,Kaminski MS.Therapywithunlabeled and131IͲlabeled panͲ
BͲcellmonoclonal antibodies innudemicebearingRajiBurkitt'slymphoma xenografts. CancerRes.
1992;52(23):6476 Ͳ6481.
13.Huneke RB,Pi[INVESTIGATOR_112812]CG,SquireRA,Brechbiel MW,Gansow OA,StrandM.EffectivealphaͲparticleͲ
mediated radioimmunothe r
apyofmurineleukemia. CancerRes.1992;52(20):5818 Ͳ5820.
14.RubleG,WuC,SquireRA,GanswoOA,StrandM.Theuseof212PbͲlabeledmonoclonal antibodyin
thetreatment ofmurineerythroleukemia. IntJRadiatOncolBiolPhys .1996;34(3):609 Ͳ616.
15.LenhardRE,Jr.,Order SE,Spunber gJJ,AsbellSO,LeibelSA.Isotopicimmunoglobulin: anewsystemic
therapyforad
vancedHodgkin's disease.JClinOncol.1985;3(10):1296 Ͳ1300.
16.RosenST,ZimmerAM,GoldmanͲLeikin R,etal.Radioimmunodetection andradioimmunotherapy of
cutaneous Tcelllymphomas usingan131IͲlabeledmonoclonal antibody: anIllinoisCancerCouncil
Study.JClinOncol .1987;5(4):562 Ͳ573.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page44of6217.DeNardoGL, DeNardoSJ,O'GradyLF,LevyNB,AdamsGP, MillsSL.Fractionated 
radioimmunotherapy ofBͲcellmalignancies with131IͲLymͲ1.CancerRes.1990;50(3 Suppl):1014s Ͳ
1016s.
18.Scheinberg DA,StrausDJ,Yeh SD,etal.AphaseItoxicity,pharmacology, and dosimetry trial of
monoclonal antibodyOKB7 inpatientswithnonͲ Hodgkin 'slymphoma: effectsof tumorburdenand
antigenexpression. JClinOncol .1990;8(5):792 Ͳ803.
19.ParkerBA,VassosAB,HalpernSE,etal.Radioimmunotherapy ofhumanBͲcelllymphoma with90YͲ
conjugated antiidiotype monoclonal antibody. CancerRes.1990;50(3 Suppl):1022s Ͳ1028s.
20.Vriesendorp HM,HerpstJM,GermackMA,etal.PhaseIͲIIstudiesofyttriumͲlabeledantiferritin 
treatme n
tforendͲstage Hodgkin's disease,includingRadiation TherapyOncology Group87Ͳ01.J
ClinOncol .1991;9(6):918 Ͳ928.
21.Goldenberg DM,HorowitzJA,SharkeyRM,etal.Targeting, dosimetry, andradioimmunotherapy of
BͲcelllymphomas withiodineͲ131Ͳlabeled LL2monoclonal antibody[seecomments]. JClinOncol .
1991;9(4):54 8Ͳ
564.
22.Waldmann TA,PastanIH,Gansow OA,Junghans RP.Themultichain interleukin Ͳ2receptor: atarget
forimmunotherapy. AnnInternMed .1992;116(2):148 Ͳ160.
23.Papadopoulos EB,CaronPC,CastroͲMalaspi[INVESTIGATOR_28947] H,etal.Resultsofallogeneic bonemarrowtransplant 
following 131IͲM195/busulfan/cyclophosphamide (BU/CY)inpatientswithadvanced/refractory
myeloid malignancies. Blood .1993;82:80a. 
24.PaganelliG,Riva P,Deleide G,etal.Invivolabellingofbiotinylated monoclonal antibodies by
radioactive avidin:astrategytoincreasetumorradiolocalization. IntJCancerSuppl .1988;2:121 Ͳ125.
25.Kaminski MS,ZasadnyKR,FrancisIR,etal.Radioimmunotherapy ofBͲcelllymphoma with[131 I]antiͲ
B1(antiͲ
CD20)antibody. NEnglJMed .1993;329(7):459 Ͳ465.
26.PressOW, EaryJF,Appelbaum FR,etal.Radiolabeled Ͳantibody therapyofBͲcelllymphoma with
autologous bonemarrowsupport [seecomments]. NEnglJMed .1993;329(17):1219 Ͳ1224.
27.SchwartzMA,LovettDR,RednerA,etal. DoseͲescalation trial ofM195labeledwithiodine131for
cytoreduction and marrowablation inrelapsedorrefractory myeloid leukemias. JClinOncol .
1993;11(2):294 Ͳ303.
28.PressOW, EaryJF,Appelbaum FR,etal.PhaseIItrial of131IͲB1(antiͲCD20)antibodytherapy with
autologous stemcelltransplantation forrelapsedBcelllymphomas. Lancet .1995;346(8971):336 Ͳ
340.
29.Waldmann TA,White JD,Carrasquillo JA,etal.Radioimmunotherapy ofinterleukin Ͳ2RalphaͲ
expressing adult
TͲcellleukemiawithYttriumͲ90 Ͳlabeled antiͲTac.Blood. 1995;86(11):4063 Ͳ4075.
30.Matthews DC,Appelbaum FR,EaryJF,etal.Development ofamarrowtransplant regimenfo racute
leukemiausing targetedhematopoietic irradiation delivered by131IͲlabeledantiͲCD45 antibody, 
combined withcyclophosphamide andtotal bodyirradiation. Blood .1995;85(4):1122 Ͳ1131.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page45of6231.KnoxSJ,GorisML,TrislerK,etal.YttriumͲ90Ͳlabeled antiͲCD20monoclonal antibodytherapy of
recurrent BͲcelllymphoma. ClinCancerRes.1996;2(3):457 Ͳ470.
32.DeNardoGL,Lamborn KR,Goldstein DS,KrogerLA,DeNardoSJ.Increased survivalassociated with
radiolabeled LymͲ1therapyfornonͲHodgkin's lymphoma andchroniclymphocytic leukemia.Cancer .
1997;80(12 Suppl):2706 Ͳ
2711.
33.JurcicJG,LarsonSM,SgourosG,etal.Targetedalphaparticleimmunotherapy formyeloid leukemia. 
Blood .2002;100(4):1233 Ͳ1239.
34.Matthews DC,Appelbaum FR,EaryJF,etal.PhaseIstudyof(131)IͲantiͲCD45 antibodyplus
cyclophosphamide and totalbodyirradiation foradvanced acuteleukemiaandmyelody splastic
syndrome. Blood. 1999;94(4):1237 Ͳ1247.
35.O'Donoghue JA.Optimaltherapeutic strategies forradioimmunotherapy. RecentResultsCancerRes.
1996;141:77 Ͳ99.
36.Clift RA,BucknerCD,Appelbaum FR,etal.Allogeneic marrowtransplantation inpatientswithacute
myeloid leukemiainfirstremission: arandomized trial oftwoirradiation regimens. Blood .
1990;76(9):1867 Ͳ1871.
37.Clift
RA,BucknerCD, Appelbaum FR,etal.Allogeneic marrowtransplantation inpatientswith
chronic myeloidleukemiainthechronic phase: arandomized trial oftwoirradiation regimens. 
Blood .1991;77(8):1660 Ͳ1665.
38.SchroffRW,Foon KA,Beatty SM,OldhamRK,MorganAC,Jr.Human antiͲmurineimmunoglobulin 
responses inpatientsreceivingmonoclonal antibodytherapy.CancerRe
s.1985;45(2):879 Ͳ885.
39.ShawlerDL,Bartholomew RM,SmithLM,DillmanRO.Humanimmuneresponsetomultiple
injections ofmurinemonoclonal IgG.JImmunol .1985;135(2):1530 Ͳ1535.
40.Scheinberg DA,LovettD,DivgiCR,etal.AphaseItrial ofmonoclonal antibodyM195inacute
myelogenous leukem ia:
specificbonemarrowtargetingand internalization ofradionuclide. JClin
Oncol .1991;9(3):478 Ͳ490.
41.RuffnerKL,Matthews DC.Currentusesofmonoclonal antibodies inthetreatment ofacuteleukemia
[InProcess Citation]. SeminOncol .2000;27(5):531 Ͳ539.
42.Appelbaum F,Matthews D,EaryJF,etal.Theuseofradiolabeled antiͲCD33 antibodytoaugment
marrowirradiation priortomarrowtransplantation for acutemyelogenous leukemia. 
Transplantation .1992;54(5):829 Ͳ833.
43.BunjesD,Buchmann I,DunckerC,etal.Rhenium188ͲlabeledantiͲCD66 (a,b,c,e)monoclonal 
antibodytointensifytheconditioni ngregimenpriortostemcel ltransplantation forpatientswith
highͲriskacutemyeloid leukemiaormyelodysplastic syndrome: resultsofaphaseIͲIIstudy.Blood .
2001;98(3):565 Ͳ572.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page46of6244.BurkeJM,CaronPC,Papadopoulos EB,etal.Cytoreduction withiodineͲ131ͲantiͲCD33 antibodies 
beforebonemarrowtransplantation foradvanced myeloid leukemias. BoneMarrow Transplant .
2003;32(6):549 Ͳ556.
45.BurkeJM,JurcicJG,Scheinberg DA.Radioimmunotherapy foracuteleukemia. CancerControl .
2002;9(2):106 Ͳ113.
46.SgourosG,Ballangrud AM,JurcicJG,etal.Pharmacokine ticsand dosimetry ofanalphaͲparticle
emitter labeled antibody: 213BiͲHuM195 (antiͲCD33)inpatientswithleukemia. JNucl Med .
1999;40(11):1935 Ͳ1946.
47.ValleraD,ElsonM,Brechbiel M,etal.Preclinical studiestargetingnormaland leukemic
hematopoietic cellswithyttriumͲ90Ͳlabeled antiͲCD45 antibodyinvitroand invivoinnudemice.
CancerBiother Radiophar m.2003;18(2 )
:133Ͳ145.
48.JurcicJG,DeBlasioT,DumontL,YaoTJ,Scheinberg DA.Molecular remission induction withretinoic
acidandantiͲCD33 monoclonal antibody HuM195 inacutepromyelocytic leukemia. ClinCancerRes.
2000;6(2):372 Ͳ380.
49.Klein SA,Hermann S,DietrichJW,Hoelzer D,MartinH.Transplantation Ͳrelatedtoxi cityandacute
intestinal graftͲversusͲhostdisease after conditioning regimens intensified withRhenium 188Ͳ
labeledantiͲCD66 monoclonal antibodies. Blood .2002;99(6):2270 Ͳ2271.
50.OmaryMB,Trowbridge IS,BattiforaHA.Humanhomologue ofmurineT200glycoprotein. JExpMed .
1980;152(4):842 Ͳ852.
51.TaetleR,Ostergaard H,Smedsrud M,Trowbridge I.Regulatio
nofCD45 expression inhuman
leukemiacells.Leukemia .1991;5(4):309 Ͳ314.
52.NakanoA,Harada T,Morikawa S,KatoY.Expression ofleukocyte commonantigen(CD45) on
varioushumanleukemia/lymphoma celllines.ActaPathol Jpn.1990;40(2):107 Ͳ115.
53.AndresTL,KadinME. Immunologic markersinthedifferential diagnosis ofsmallroundcelltumors
fromlymphocytic lymphomaandleuke
mia.AmJClinPathol .1983;79(5):546 Ͳ552.
54.CaldwellCW, Patterson WP,Hakami N.Alterations ofHLeͲ1(T200)fluorescence intensity onacute
lymphoblastic leukemiacellsmayrelate totherapeutic outcome. LeukRes.1987;11(1):103 Ͳ106.
55.RosarioE,JGR,RuffnerKL,etal.Radiolabeled antiͲ
CD45 withcyclophosphamide (CY) andtotalbody
irradiation (TBI)followedbyallogeneic hematopoietic stemcelltransplantation (HSCT)forpatients
withadvanced acutemyeloid leukemia(AML)ormyelodysplastic syndrome. Blood .2001;98:857a 
[Abstract]. 
56.RuutuT,Hanninen A,JarventieG,etal.Intensive chemotherapy ofpoor prognosis myelodysplastic
syndromes (MDS)andacutemyeloidleu
kemiafollowing MDSwithidarubicin and cytarabine. Leuk
Res.1997;21(2):133 Ͳ138.
57.BennettJM,YoungML,Andersen JW,etal.LongͲtermsurvivalinacutemyeloidleukemia: the
EasternCooperative Oncology Groupexperience. Cancer .1997;80(11 Suppl):2205 Ͳ2209.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page47of6258.Lowenberg B,SuciuS,Archimbaud E,etal.Mitoxantrone versusdaunorubicin ininduction Ͳ
consolidation chemotherapyͲͲthe valueoflowͲdosecytarabine formaintenance ofremission, and
anassessment ofprognostic factorsinacutemyeloidleukemiaintheelderly:finalreport.European 
Organization fortheResearchand Treatment ofCancerand theDutchͲBelgianHematoͲOnc ology
Cooperative HovonGroup.JClinOncol
.1998;16(3):872 Ͳ881.
59.Giralt S,EsteyE,AlbitarM,etal.Engraftment ofallogeneic hematopoietic progenitor cellswith
purineanalogͲcontaining chemotherapy: harnessing graftͲversusͲleukemia withoutmyeloablative 
therapy.Blood .1997;89(12):4531 Ͳ4536.
60.SlavinS,Nagler A,Naparstek E,etal.Nonmyeloablative stemcelltransplantation andcelltherapyas
analternative toconventional bonemarrowtransplantation withlethalcytoreduction for
the
treatment ofmalignant andnonmalignant hematologic diseases.Blood .1998;91(3):756 Ͳ763.
61.NaglerA,SlavinS,VaradiG,Naparstek E,SamuelS,OrR.Allogeneic peripheral blood stemcell
transplantation usingafludarabine Ͳbasedlowintensit yco
nditioning regimenfor malignant 
lymphoma. BoneMarrowTransplant .2000;25(10):1021 Ͳ1028.
62.ChildsR,Clave E,Contentin N,etal.Engraftment kineticsafter nonmyeloablative allogeneic 
peripheral blood stemcelltransplantation: fulldonorTͲcellchimerism precedes alloimmune 
responses. Blood .1999;94(9):3234 Ͳ3241.
63.Spi[INVESTIGATOR_626]TR,McAfeeS,Sackstein R,etal.Intentional induction ofmixed chime rismand achievement 
ofantitumor responses after nonmyeloablative conditioning therapy andHLAͲmatcheddonorbone
marrowtransplantation forrefractory hematologic malignancies. BiolBloodMarrow Transplant .
2000;6(3A):309 Ͳ320.
64.Sandmaier BM,MaloneyDG,GooleyTA,etal.LowdoseTBIconditioning forhematopoieti cstemcell
transplants (HSCT)fromHLAͲ
matchedrelateddonorsforpatientswithhematologic malignancies: 
influence offludarabine orcytoreductive autografts onoutcome. Blood .2002;100:145a [Abstract]. 
65.Kottaridis PD,MilliganDW, ChopraR,etal.InvivoCAMPATHͲ1H preventsgraftͲversusͲhostdisease
following nonmyeloablative stemcelltransplantation. Blood .2000;96(7):2419 Ͳ2425.
66.SykesM,PrefferF,McA
feeS,etal.Mixedlymphohaemopoietic chimerism and graftͲversusͲ
lymphoma effectsafternonͲmyeloablative therapyandHLAͲmismatched boneͲmarrow 
transplantation. Lancet .1999;353(9166):1755 Ͳ1759.
67.NaglerA,AkerM,OrR,etal.LowͲintensity conditioning issufficient toensureengraftment in
matchedunrelatedbonemarrowtransplantation. ExpHe
matol .2001;29(3):362 Ͳ370.
68.Bornhauser M,ThiedeC,Platzbecker U,etal.DoseͲreducedconditioning andallogeneic 
hematopoietic stemcelltransplantation fromunrelated donorsin42patients.ClinCancerRes.
2001;7(8):2254 Ͳ2262.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page48of6269.Chakraverty R,Peggs K,ChopraR,etal.Limitingtransplantation Ͳrelated mortalityfollowing 
unrelated donorstemcelltransplantation byusinganonmyeloablative conditioning regimen.Blood .
2002;99(3):1071 Ͳ1078.
70.Niederwieser D,MarisM,ShizuruJA,etal.LowͲdose total bodyirradiation (TBI)andfludarabine 
followedbyhematopoietic celltransplantation (HCT) fromHLAͲmatchedormismatched unrelate d
donorsandpostgrafting immunosuppr
essionwithcyclosporine and mycophenolate mofetil(MMF)
caninducedurablecomplete chimerism andsustained remissions inpatientswithhematological 
diseases.Blood .2003;101(4):1620 Ͳ1629.Epub2002Oct1623.
71.MarisMB,Niederwieser D,Sandmaier BM,etal.HLAͲmatched unrelated donorhematopoietic cell
transplantation after nonmyeloablative condi tioningfor
patientswithhematologic malignancies. 
Blood .2003;102(6):2021 Ͳ2030.Epub2003Jun2025.
72.McSweeney PA,Niederwieser D,ShizuruJA,etal.Hematopoietic celltransplantation inolder
patientswithhematologic malignancies: replacinghighͲdosecytotoxictherapywithgraftͲversusͲ
tumoreffects.Blood .2001;97(11):3390 Ͳ3400.
73.Gyurkocza B,Storb R,Storer B,etal.Nonmyeloablative Allogenei cHematopo ieticCell
Transplantation inPatientswithDeNovo
and Secondary AcuteMyeloidLeukemia. Blood .
2008;112(11). 
74.KahlC,Storer BE,Sandmaier BM,etal.Relapseriskinpatientswithmalignant diseasesgiven
allogeneic hematopoietic celltransplantation afternonmyeloablative conditioning. Blood.
2007;110(7):2744 Ͳ2748.
75.LaportGG,SandmaierBM,Storer
BE,etal.ReducedͲintensity conditioning followedbyallogeneic 
hematopoietic celltransplantation foradultpatientswithmyelodysplastic syndrome and
myeloproliferative disorders. BiolBloodMarrow Transplant .2008;14(2):246 Ͳ255.
76.StuartMJ,CaoTM,Sandmaier BM,etal.EfficacyofnonͲmyeloablative allogeneic transplant for
patientswithmyelodysplastic syndrome (MDS)andmyelopro liferative
disorders (MPD) (except
chronicmyelogenous leukemia). Blood .2002;102:185a [Abstract]. 
77.PagelJM,GooleyTA,Rajendran J,etal.Allogeneic hematopoietic celltransplantation after
conditioning with131IͲantiͲCD45 antibodyplusfludarabine and lowͲdosetotal bodyirradiation for
elderlypatientswithadvanced acut emyeloid leukemiaorhighͲriskmyelodysplastic syndrome. 
Blood .2009;114(27):5444 Ͳ5453.Prepublished on2009/09/30 asDOI10.1182/blood Ͳ2009Ͳ03Ͳ
213298.
78.Nemecek ER,HamlinDK,FisherDR,etal.Biodistribution ofyttriumͲ90ͲlabeledantiͲCD45 antibodyin
anonhuman primatemodel.ClinCancer Res.2005;11(2 Pt1):787Ͳ794.
79.Storer BE. SmallͲsampleconfidence setsfor
theMTDinaphaseIclinicaltrial.Biometrics .
1993;49(4):1117 Ͳ1125.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page49of6280.Krishnan A,Nademanee A,FungHC,etal.PhaseIItrial ofatransplantation regimenofyttriumͲ90
ibritumomab tiuxetanandhighͲdosechemotherapy inpatientswithnonͲHodgkin's lymphoma. JClin
Oncol .2008;26(1):90 Ͳ95.Prepublished on2007/11/21 asDOI10.1200/jco.2007.11.9248. 
81.ShimoniA,ZwasST,OksmanY,etal.YttriumͲ90Ͳ ibritumomab tiuxetan(Zevalin) combined with
highͲdoseBEAMchemotherapy and autologous stemcelltransplantation forchemoͲrefractory 
aggressive nonͲHodgkin's lymphoma. ExpHematol. 2007;35(4):534 Ͳ540.Prepublished on
2007/03/24 asDOI10.1016/j.exphem.2007.01.043. 
82.Nademanee A,FormanS,MolinaA,etal.Aphase1/2trial ofhighͲdoseyttriumͲ90 Ͳibritumomab 
tiuxe t
anincombination withhighͲdose etoposide and cyclophosphamide followedbyautologous 
stemcelltransplantation inpatientswithpoorͲriskorrelapsednonͲHodgkin lymphoma. Blood .
2005;106(8):2896 Ͳ2902.
83.WinterJN,InwardsDJ,Spi[INVESTIGATOR_014]S,etal.YttriumͲ90 ibritumomab tiuxetan dosescalculated todeliverup
to15Gytocriticalorgansmaybesafelycombined withhighͲdoseBEAMandautologous 
transplantation inrelapsedorrefractory BͲcellnonͲ
Hodgkin's lymphoma. JClinOncol .
2009;27(10):1653 Ͳ1659.
84.DevizziL,GuidettiA,TarellaC,etal.HighͲdoseyttriumͲ90Ͳibritumomab tiuxetanwithtandemstemͲ
cellreinfusion: anoutpatient preparative regimenfor autologous hematopoietic cell
transplantation. JClinOncol .2008;26(32):5175 Ͳ5182.Prepublished on2008/10/16 asDOI
10.1200/jco.2008.16.8294. 
85.Cremonesi M,FerrariM,GranaCM,etal.
HighͲdose radioimmunotherapy with90YͲibritumomab 
tiuxetan:comparative dosimetric studyfortailoredtreatment. JNucl Med .2007;48(11):1871 Ͳ1879.
Prepublished on2007/11/06 asDOI10.2967/jnumed.107.044016. 
86.FerrucciPF,VanazziA,Grana CM,etal.Highactivity90YͲibritumomab tiuxetan(Zevalin)with
peripheral blood progenitor cellssupportinpatientswithrefractory/resistant BͲcellnonͲHodgki n
lymphomas. BrJHaematol .2007 ;139(4):590 Ͳ
599.Prepublished on2007/11/06 asDOI
10.1111/j.1365 Ͳ2141.2007.[ZIP_CODE].x. 
87.Emami B,LymanJ,BrownA,etal.Tolerance ofnormaltissuetotherape uticirradiation. IntJRadiat
OncolBiolPhys .1991;21(1):109 Ͳ122.Prepublished on1991/05/15 asDOI.

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page50of62APPENDIX A: BEARMAN CRITERIA FORREGIMEN ͲRELATED TOXICITY 
Thecriteria fortoxicityweredeveloped toconvey thefollowing considerations about thetoxicityofthe
preparative regimen.Itistheresponsibility oftheprincipalinvestigator totryanddistinguish toxicities
duetothepreparative regimenfromtheseduetoother featuresoftransplantation. 
Grade1Development oftransient chemical abnormalities whicharenotofmajorclinical
conseque
nceandwhichreversewithoutrequiringmajor medicalinterventions.In general,
theintentofthistoxicityscale istoobservetransient target organtoxicitywhich is
reversible. 
Grade2Development ofchemicalorlaboratory abnormalities whicharepersistent andwhich may
represent targetorgandamage which maynotbereadilyreversed. Itisanti cipatedthatat
thisdoseofdrug,thetoxicityobtainedwouldbemanageable byclinicalmethodsbutmay
interferewithothertherapi[INVESTIGATOR_014]. 
Grade3Development ofmajor clinical,chemicalorlaboratory abnormalities whichrepresent
maximum toxicitieswithoutbeing fatal.Thisgradeoftoxicityisdesigned tobethedose
limitingtoxicity.Further,
thedevelopment ofthisdegreeoftoxicitycannot beconsidered to
bearegularacceptable butrather anoccasional toxicity(<20%), acceptable giventhe
severity ofthedisease.Included inthiswouldbetheneedforlifesupport techniques such
asrenaldialys isand ventilation therapy.
Grade4Fatal.
A. Cardiac
Grade1EKGvoltagedecreaseby25%orless, resting tachycardia withweightgain butresponsive to
diuretic therapy.
Grade2EKGvoltagedecreaseby25Ͳ50%,congestive heartfailure responsive todiuretictherapy,
arrhythmias manageable withmedicaltherapy.
Grade 3Sympto maticCHFunresponsive todiuretictherapy, decreaseinEKGvoltagebymorethan
50%,lifeͲthreatening arrhythmia. 
Grade4Fataltoxicity.
B. Bladder
Grade1Microscopic hematuria formorethan7days.
Grade2Macroscopic hematuria. 
Grade3Hemorrhagic cystitisrequiring transfusion and placement ofanindwelling catheter to
removeclots,orcystoscopy withorwithout installation ofsclerosing agents.
Grade4Fataltoxicity .
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page51of62C. Renal
Grade1Increaseincreatinine uptotwicebaselinevalue.
Grade2Increaseincreatinine abovetwice baselinevaluebutnotrequiringdialysis.
Grade3Requirement ofdialysis.
Grade4Fataltoxicity.
D. Pulmonary
Grade1Decrease inpO2ordyspneawithout aninfiltrateor,atmost,atransientpatchyinfiltrate. 
Grade2Transient interstitial pn
eumonia (eitheridiopathic orunbiopsied) thatdoesnotrequire
ventilatory support).
Grade3Interstitial pneumonia requiring ventilatory support.
Grade4Fataltoxicity.
E. Hepatic
Grade1Transient elevations inliverfunctiontestslessthanthoselistedasGrade2toxicity.
Grade2Hepatic dysfunction withbilirubinelevation greaterthan5,SGOTincreasegreaterthanfiveͲ
foldorascites.
Grade3Hepati
cfailure includinghepatoͲrenalsyndrome, hepatic encephalopathy, bilirubin
elevation greaterthan20,orGrade3VODasdefinedbyShulmanetal.
Grade4Fataltoxicity.
F. Central Nervous System
Grade1Transient somnolence. 
Grade2Somnolence morethan36hoursorothersignsofCNStoxi
city.
Grade3Seizuresorcoma.
Grade4Fatal.
G. Stomatitis 
Grade1Ulceration orpainbutnotprohibiting oralintake.
Grade2Painfululceration prohibiting oralintake.
Grade3Severeulceration requiringintubation. 
Grade4Fatal.
H. Gastrointestinal
Grade1Waterystools,butlessthan6stools/day. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page52of62Grade2Waterystoolsmorethan6Ͳ12stools/day, orhemorrhagic enterocolitis notrequiring
transfusion, ortransientileus.
Grade3Hemorrhagic enterocolitis requiringtransfusion, orileusrequiringnasogastric suction.
Grade4Fatal.


 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page53of62APPENDIX B: ACUTEGVHDASSESSMENT 

StagingbyIndividual OrganInvolvement 

SKIN: measured byrashfirstappearing generally between10and70daysafter transplant. 
(excludes rashesofknownviralorotherorigin)

Stage Description 
1 Maculopapular rash<25%BSA
2 Maculopapular rash25–50%BSA
3 Generalized erythroderma 
4Generalized erythroderma with
bullousformation anddesquamation 
LIVER*:measured bytotal serumbilirubin

Stage Description 
1 2.0–2.9mg/dL
2 3.0–5.9mg/dL
3 6.0–14.9mg/dL
4 >15.0mg/dL

GUT**: includesonlydiarrheaoccurring afterDay+21

Score Adult Pediatric*** 
1upperGI(anorexia, nausea,vomiting) 
withdiarrheaof<1000mL/dayupperGI(anorexia, nausea,vomiting) 
withdiarrheaof<555mL/m2/day
2 1000–1499mL/day diarrhea 556Ͳ833mL/m2/day diarrhea
3 >1500mL/day diarrhea >833mL/m2/daydiarrhea
4 severeabdominal crampi[INVESTIGATOR_007], bleedingorileuscausedbyGVHD
*Incaseswhereanothercauseofhyperbilirubinemia antedated theonsetofrash, theliverscore
shouldbedecreased byonestage.
**IncaseswherepeakGIsymptoms areexacerbated byacause other thanGVHD,thegutscore
shouldbedecreased byonestage.
***Pediatricpatients<17yearsofage

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page54of62Overall Grade

Thedetermination ofanoverallGVHDgradeshouldbebasedontheorganstage,responsetotreatment 
andwhetherGVHDwasamajor cause ofdeath.

Overall
GradeOrganStage Qualifying Conditions  Additional Qualifying Conditions 
I Stage 1Ͳ2skin NoliverorgutIndicatesthattheprophylactic 
immunosuppressive regimenwasnot
sufficient topreventallmanifestations of
aGVHD.
IIStage 3skin
 or
Stage 1liver
 or
Stage 1gutN/AIndicatesthattheprophylactic 
immunosuppressive regimenwasnot
sufficient topreventallmanifestations of
aGVHD, butglucocorticoid treatment after
theonsetofGVHDwasgenerallysufficient 
tocontrolthedisease.
IIIStage 4skin
 or
Stage 2Ͳ4liver
 or
Stage 2Ͳ4gutwithoutGVHDasamajor
contributing cause ofdeath

Indicatesthattheprophylactic 
immunosuppressive regimenwasnot
sufficient topreventallmanifestations of
aGVHDandthatadditional treatment after
theonsetofGVHDdidnotreadilycontrol
thedisease.
IVStage 4skin
 or
Stage 2Ͳ4liver
 or
Stage 2Ͳ4gutwithGVHDasamajor
contributing cause ofdeath
GVHDwasresistanttoboththe
prophylactic immunosuppressive regimen
andanyadditional treatment afterthe
onsetofthedisease.

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page55of62APPENDIX C: CHRONIC GVHDGRADING* 
Inallcases,concomitant processes (i.e.infections ordrugreactions) mustberuled out.Karnofsky or
LanskyClinicalPerformance scores,60%,>15%weightloss,andrecurrent infections areusuallysignsof
clinicalextensive chronic GVHD. Abnormalities thatcouldindicatechronicGVHDarecategorized by
organsystems aslistedbelow.

SkinErythema, dryness,pruritus,pi[INVESTIGATOR_112813]changes(i
.e.hyperpi[INVESTIGATOR_371], vitiligo),
mottling,papulosquamous plaques,nodules,exfoliation, macularͲpapularor
urticarialrash, scleroderma, morphea(oneorseveralcircumscribed, indurated and
shinylesions)
Nails Ridging,onychodystrophy, onycholysis 
HairPremature graying,(scalphair,eyelashes, eyebrows), thinningscalphair,alopecia,
decreased bodyhair
MouthDryness,burning,gingivitis, mucositis, striae, atrophy,erythema, lichenoidchanges,
ulcers,labialatrophyorpi[INVESTIGATOR_112814] changes,toothdecay, tightnessaroundthe
mouth
Eyes Dryness,burning,blurring,grittyeyes,photophobia, pain
Vagina/vulva Dryness,dyspareunia, strictureorstenosis,erythema, atrophyorlichenoidchanges
notincluded
LiverElevated liverfunction testsnotduetoothercauses(alkalinephosphatase t3x
upperlimitofnormal,ASTorALTt4xupperlimitofnormalortotal serumbilirubint
2.5;intheabsenceofchronic GVHDinvolvingotherorgans, liverbiopsyisrequired
toconfirmdiagnosis) 
LungBronchiolitis obliterans (see diagnostic indicators), cough,wheezing, dyspnea on
exertion,historyofrecurrent bronchitis orsinusitis
GI Anorexia, nausea,vomiting, weightloss,dysphasia, odynophagia, malabsorption 
FasciitisStiffnessandtightnesswithrestriction ofmovement, occasionally withswellingpain,
crampi[INVESTIGATOR_007], erythema and induration, mostcommonly affectingforearms, wristsand
hands,ankles,legs, andfeet,inabilitytoextendwristswithoutflexingthefingers or
theelbows,contractures 
Serositis Chestpainorcardiopulmonary compriseduetopericarditis orpleuritis
Muscle Proximalmuscleweakness, crampi[INVESTIGATOR_007] 
Skeletal Arthralgia oflargeproximal girdlejointsandsometimes smallerjoints

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page56of62Laboratory testinganddiagnostic indicators ofchronicGVHD*
EyeSchirmer’s testwithameanvalued5mmat5minutes,orsymptomatic with
valuesof6Ͳ10mmorkeratitisdetectedbyslitlampexamination 
LiverElevated liverfunctiontestsnotduetoothercauses(seedefinition ofclinical
limitedandextensive chronic GVHD)
LungNewobstructive lungdefect defined asFEV1<80%ofpredicted witheitheran
FEF25Ͳ75<65%ofpredicted orRV>120%ofpredicted, oradecreaseof
FEV1/FVC by>12%withinaperiodoflessthan1year.Adiagnosis of
bronchiolitis obliterans requiresnegativemicrobiological testsfrom
bronchoalveo larlavageand
evidenceofairtrappi[INVESTIGATOR_007]byhighresolution endͲ
expi[INVESTIGATOR_696] and endͲinspi[INVESTIGATOR_696] CATscansothechest.Athoracoscopic lung
biopsymaybenecessary inorder toconfirm thediagnosis ofbronchiolitis 
obliterans inpatientswhohaveobstructive lungdisease withoutairtrappi[INVESTIGATOR_007]
whenchronicGVHDinvolvingother orga nsisabsent
Esophagus Esophageal webformation, strictureordysmotility demonstrated bybarium
swallow,endoscopy ormanometry 
Muscle ElevatedCPKoraldolase,EMGfindingsconsistent withmyositis
BloodThrombocytopenia  (usually 20,000Ͳ100,000/ Pl), eosinophilia, 
hypogammaglobulinemia, hypergammaglobulinemia, and autoantibodies occur
insome cases

*FromStandard PracticeGuidelines for“ChronicGraftͲversus ͲHostDiseaseClassification atthetime of
presentation” developed byLongTermFollowͲUpattheFHCRC

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page57of62APPENDIX D: METHODS USEDTOCALCULATE RADIATION ABSORBED 
DOSESTOPATIENTS
a.ScientificBasisforInternalDosimetry Calculations 
Radiation absorbed doseswillbecalculated foreach patient’snormalorgansandtissuesandthewhole
bodyusingstandard methodsrecommended bytheMedicalInternalRadiation Dose(MIRD)Committee 
ofTheSocietyofNuclearMedicine (Loevinger etal.,1991).TheMIRDmethodsaccountforboththe
penetrating gammaandthenonͲpe netratingbetaradiation(ele ctrons)emittedbyradioactivity 
distributed throughout thebody.Thepharmacokinetics andbiodistribution oftheradiolabeled 
antibodywillvaryfromonepatienttothenext.Therefore, intheMIRDschema,dosimetry calculations 
arebasedonaseriesofdirect measurements oftheorganbiodistribution ofradiolabeled antibody. 
These includegammaͲcameraimagesand quantitative activitymeasurements oftheradionuclide used
(111Inasasurrogate foryttriumͲ90Ͳlabeledantibody) inthemajorimageable sourceorgans, tumor
tissue,redmarrow,andthetotal bodyatvarioustimeͲpoints postͲinfusion. Marrowtissuebiopsiesare
weighedandcountedtodetermine theactivityconcentration inmarrowatspecifictime points.When
available, thepatientͲspecific organmasses areused forinternal dosecalculations rather thangeneric
model values.Themathematical foundations forapplica tionoftheseme
thodstocriticalorgansinhighͲ
doseradioimmunotherapy arewellͲestablished (Fisher1994,2000;Fisheretal.2009).
b.Rationale fortheUseofIndiumͲ111toPredictYttriumͲ 90Biodistribution forDecidingthe
Administered activityofTherapy
Because90Yisapure betaͲemitter,itcannotbeimagedaccurately orconveniently inthepatient,and
activityover timeintheindividual organscannotbeeasilydelineated. ThephotonͲemittingindiumͲ111
labelstheantibodytoshow thebiodistribution of90YͲantibody. Weassume thatthebiodistribution of
thetraceͲlabeled111Inantibodyfaithfullyrepresents thebiodistribution of90Yantibodyinthecancer
patient.Preclinical studiesbyothers confirm thatthebiodistribution of111Inantibodyusuallycorrelates
with90Yantibodybiodistribution (Fisheretal.2009).Therefore, itiscommonpracticetouse111In
antibodymeasurement datatopredictthebiodistribution of90YͲantibody duringtherapy.Inabsolute
terms,thiscorrelation maynotbecompletely correct,however, becausepartial dissociation of90Yand
111Infromtheimmunoconjugate mayoccurinvivo;some ofthefree90Ymaydepositonbone surfaces,
andsome ofthe111Inmaypreferentially gotothetestesduetonaturaluptakeofindiumbygermcells.
Duringradiolabeling, qualitycontrolusuallyallowslessthan2%unbound111Ininthe
radioimmunoconjugate. Wewillnotmeasuretheunboundfractioninserumafter injection. For
dosimetry calculations, however, wewillassume thatthebiodistributions of111InͲand90YͲlabeled
antibodyareequivalent, recognizing thatwithoutfurthercorrection thisassumption may, insome
cases,leadtominorunderestimates of90Ydosetobonesurfacesand redmarrow,andtominor
overestimates of90Ydosetothetestes.
c.Direct Measurements inPatients
(i)Conjugate Ͳview quantitative planarimagingwithanteriorand posteriormeasurements isthemost
widelyusedmethodforassessing sourceͲorganactivityinpatients.Theconjugate view methoddoes
notrequireknowing thedepthofthesourceregionand doesnotdependonassumptions inherentin
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page58of62singleͲview phantom simulations, butdoesincorporate correction forbackground, scatter,and photon
attenuation. 
(ii)Biodistribution Imaging
Afteratracerquantityof111In(usually111to222MBqor3to6mCi)labeled toDOTAͲBC8is
administered, thepatientisimagedusing collimated anteriorand posteriorplanargammaͲcamera
imaging.Biodistribution imagingbeginsimmediately after infusionof111IntraceͲlabeled DOTAͲBC8on
day0.Anuclearmedicinecamerawithamediumenergycollimator, withphotopeak settingsat171and
245keV, and asymmetric 15%windowaroundeach photopeak, isused forimaging.Imagesinclude
chestwithupperhumeriand thyroid,abdomen, andpelviswithupperfemurs.Regionsofinterestare
alwaysselectedforthemajorsourceorgansthatvisualizeabovebackground, whichmayincl
ude,but
arenotlimitedto,theliver,spleen,heartvolume,redmarrowspace,lungs,kidneys, thyroid,andtestes.
Normalorgansand tumorsarevisualized whenconcentrations of111Inantibodyintheorganortumor
aregreaterthanthose inthesurrounding tissue.Background regionsaredrawnforeach organor
regionofinterestsimilartothemethodsdescribed above.Inaddition,attenuation correction factorsare
determined forthechestandabdomen usingthemethodsdescribed below. Wemayimagetumorsites
thathavewellͲdefine duptakesandretention of
111InͲradiopharmaceuticals, allowingustodetermine 
thepercentofadministered activitypergramoftissueforallcancerous areasselectedfordose
assessment. Imagingofselectedtumorsmaybeconducted forvarioustime points,and timeͲactivity
curves maybeconstructed andintegrated fortumor doseassessments. 
Measurements arealsomadeofrepresentative back groundtissue and ofanimagingstandardwithout
thepatient inthecamera fieldͲofͲview.Theoutlinesfortheregionsofinterestaredrawnbya
technologist fromtheacquired images,andcountsareobtainedfromtheselectedregions.Thecounts
aredecayͲcorrected tothe111Inimagingstandard. Thegeometric meanoftheanteriorand posterior
countsisobtainedforeachregionofinterest.Countsarethen corrected forattenuation, decay,and
background. TotalͲbodymeasurements areobtainedusingwholeͲbodygammacameraimagesinboth
anteriorandposteriorprojections, toquantifythetotal111Inactivityremaining inthepatient,over time,
asafractionofthetotal administered activity.
(iii)Attenuation
Prior toantibodyinfusion,allpatientswillhavemeasurement madeoftheirabdomen attenuation by
transmission scans.Afluidfilledsheetsource, largeenoughtocovertheentireusefulfield ofview of
thecamera,isloadedwithapproximately 0.5–0.7mCi of111In.Uniform distribution oftheisotope
throughout thesheetsourceisensured.Thesourceisplacedonthelowerdetector,and withthe
patientonthescanningtableandtheirabdomen inthefieldofview, theupperdetectorisloweredinto
place.A fiveminutetransmission imageisacquired. Without movingthedetectors and withthe
scanningtablealone betw een
them,anotherfiveminuteimage(flood)isacquired. Theobserved ratio
ofcountsintheflood sourceactivitycountedwithandwithoutthepatient overlying istheattenuation 
correction factorforthevarious organsofinterest.
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page59of62(iv)SamplingTimes
Selectinganappropriate numberofimaging/counting timesrequirestradeͲoffs betweenhaving
sufficient dataandeconomizing theimaging costsandminimizing patientinconvenience.Our objective
istoselectthefewestdataͲcollection time pointsthatwillstillprovide areasonable evaluation ofthe
correctmathematical functionthatbestdescribes theactivityͲtimecurve . Aminimum ofthreetofour
datameasurement pointswilltypi[INVESTIGATOR_897]berequiredfor111InͲDOTAͲBC8imaging.Imaging includesone
setofmeasurements immediately post111InͲDOTAͲBC8infusion,followedbyanadditional two tothree
imagingtime pointsonDays 1and2post infusion.Forexample,apatient couldhaveimagesperformed 
duringthemorning and afternoon ofDay1,and theafternoon ofDay2,postinfusion.Theseanalyses
provide datatoestimate ofthefractionoftheadministered activitythatresides ineach source organ
andinthetotalbodyateach
measurement time postͲinfusion. 
d.TimeͲActivity Curves
Thesequential measurement dataareplottedtodetermine thecumulated activityandresidence times
foreach sourceorgan.Weplotthefractionsofthetotaladministered activityobserved ateach
measurement timepoint.Weplottheeffective data(asmeasured), rather thanthevaluesthatwere
decayͲcorrected fromaradionuclide standard, because internaldosesarecalculate dfromtheintegral
areasundertheeffectivetimeͲ
activitycurves.Wethenselectanappropriate mathematical function
(equation) withparameters thatbestrepresent thedata, andwedetermine theequation parameters by
leastͲsquareslinearregression. Wethen integrate thebestͲfitequations toinfinitetime todetermine 
theresidence times(W,hours)foreachsourceorgan,tumor,
theredmarrow,andthewholebody.We 
usuallyfitthebiodistribution datatoanexponential orsumofexponentials. Anestimate oftheslope
ofthelongͲtermtailofthetimeͲactivity curvemaybemadebyfittinganexpone ntialfunctiontothelast
twopoints.
e.Residence Ti
meCalculations: Integrating theTimeͲactivityCurves
Theresidence time(BqͲsec/BqorPCiͲhr/PCiadministered) forasourceorganisthefractionofthe
administered activityinasourceorganover time tocomplete decay, obtainedbyintegrating thetimeͲ
activitycurvetoinfinity,asdescribed inthepreviousparagraph. Residence time valuesarethebasic
inputnumbe rrequiredbysoftwarepackages
(MIRDOSE2 andMIRDOSE3 computer programs, OakRidge
Associated Universities, OakRidge,Tennessee) andOLINDAͲEXM (Vanderbilt University, Nashville, 
Tennessee) thatimplement theMIRDdosimetry schema.WewilluseOLINDAͲEXMforpatientdose
assessment onthisprotocol.
f.PatientͲspecific Dosimetry 
Sinceorgandoseisapproximately proportional totheinverseoftargetmass,acorrection shouldbe
madeforpatientweightand organmass whenactualorganweightsareobtainedbyCTͲimaging
(Rajendran etal.,2004).Theresidence timesforeach sourceorganwillbecorrected inOLINDAͲEXM
usingactualorganmass and patientweight.Ac tualpatient weightsandorgansizesvaryamong
patients,butwecancorrectforthose differences using actualorganmasses fromCTvolumetrics. 
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page60of62g.EstimateofDosetoTestes
Werecognize thatfree111Inmaydepositinthetestesduetonaturalbiokinetic processes, butthat90Y
maynot.Therefore, wewillbecareful nottoattributecountsfrom111Ininthetestes to90Yduring
therapy.
h.EstimateofDosetotheBoneMarrow:
Red marrowdosimetry isalwayschallenging inradioimmunotherapy becauseitisdifficulttoassessthe
highlyvariableconcentration ofradioactivity inmarrow and themass ofredmarrowinthepatient.
Common approaches tomarrowdosimetry oftenrelyonunreliable estimates ofradiolabeled antibody
concentration inredmarroworinredmarrowrelativetotheconcentra tionincircula tingblood orblood
plasma. Rather thanmeasureblood plasmaactivityand makeuncertain assumptions, wewillemploy
quantitative imagingof111Inindefinedmarrowspaces(acetabulum, sacrum, femoralhead,orlumbar
vertebrae) bydirect imaging.Wewillalsoobtainand countarepresentative bonemarrowbiopsy
specimen inastandardwellͲtype counter.WewillplotatimeͲactivity curvefromthemarrowimaging,
and then wewillnormalized thecurvestheknownvaluefromthebiopsyspecime n. Wewillobtaina
residence timebyintegrating themathematical functionrepresented bythenormalized exponential 
obtainedbyleastͲsquaresregression analysis.

REFERENCES: APPENDIX D
Loevinger R,BudingerTF,WatsonEEetal.MIRDPrimerforAbsorbed DoseCalculations (revised). New
York:TheSocietyofNucl e arMedicine, 1991.
FisherDR."Radiation Dosimetry forRadioimmunotherapy: AnOverview ofCurrentCapabilities and
Limitations." Cancer73(3Suppl):905 Ͳ911;1994.
Fisher,DR.“Internal Dosimetry forSystemicRadiation Therapy.” Sem.inRad.Oncol.10(2):123 Ͳ132;
2000.
FisherDR,Meredith RF,andShenS.“MIRDDoseEstimateReportNo.20:Radiation Abso rbed Dose
Estimates for111InͲand90YͲIbritumomab Tiuxetan (ZevalinTM).”JNuclMed .44(3):465 Ͳ474;2009.
Rajendran JG,FisherDR,GopalAK,DurackLD,PressOW, andEaryJF.“HighͲdose 131IͲTositumomab 
(antiͲCD20)Radioimmunotherapy fornonͲHodgkin's Lymphoma: adjustingradiationabsorbed doseto
actualorganvolumes.” J.Nucl. Med .45(6):1059 Ͳ1064;2004.







 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page61of62APPENDIX E
Potential Adverse EventsAssociated orExpected withHematopoietic CellTransplantation 

1.Graftversushostdisease:GVHDisamajor toxicityassociated withtheinfusionofallogeneic donor
stemcells.GVHDmaybeacuteorchronic andmayaffect multipleorgansystems,includingtheskin,
liver, andGItract.

2.Opportunistic infections, includingviralandfungalinfections, canresultinseverepulmonary, 
neurologic, hepaticandother organdysfunction, andpossibledeath.
3.Gastrointestinal toxicity.Nauseaandvomitingcanbeanticipated duringtheentirecourseofablative
therapy.Mucositis anddiarrheashouldbeexpected. Prednisone cancauseGIbleeding. 
4.Cardiactoxicity.Cardiotoxicity (congestive heartfailure,pericardial effusion,EKGchanges)is
uncommonly associated withthechemotherapy agentsandTBIused intheregimenandthese sequelae
mayprovelethal.

5.Pulmonary toxicity.Diffuse interstitial pneumonitis ofunknown etiologyanddiffuse alveolar
hemorrhage occurs withsomeregularity after BMTandinterstitial fibrosisoccursmuchmorerarely.
BotharewellͲdescribed complications ofintensivechemotherapy andTBIregimens andmayprove
lethal.

6.Hepatictoxicity.VenoͲocclusive disease oftheliverisacommontoxicityofhighͲdose
chemoradiotherapy andmayresultindeath.Calcineurin inhibitors maycauseelevation ofALT/AST.

7.Renaldysfunction. Chemoradiotherapy mayuncommonly causerenaldysfunction. Morecommonly, 
nephrotoxicity resultsfromcalcineurin inhibitors andgenerallyrespondstodose reduction. Rarely,
idiopathic orcalcineurin inhibitorͲassociated hemolytic Ͳuremicsyndrome mayoccurandmaybe
progressive andfatal.Asyndrome ofmoderate renalinsufficiency andhemolysis hasbeenseen5Ͳ7
monthspostHSCTafterintensive multiͲagentconditioning plusTBI.
8.Hemorrhagic cystitis,manifested either asgrossormicroscopic hema turia,isacommontoxic i
tyafter
highͲdosechemoradiotherapy, butusuallyassociated withregimens that includecyclophosphamide. 
Hemorrhagic cystitismaypredispose toalongͲtermincreased riskofbladdercancer.

9.Centralnervoussystemtoxicity.Radiation andchemotherapy cancauseCNStoxicity,including
seizures,depressed mentalstatus,orleukoencephalopathy. Calcineurin inhibitors cancauseseizuresor
otherCNStoxicity.

10.Marrowaplasia.Severeneutropenia, thrombocytopenia, andanemia, isexpectedtooccurfora
periodof7to42daysafterthepretransplant conditioning regimen.Transfusion ofplateletsandred
 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017
FHCRC Protocol 2468.00 
Page62of62blood cellsisexpectedassupportive care.Transfusion ofblood productsmaybeassociated with
acquisition ofHIVorahepatitisvirus.Neutropenia mayincreasetheriskforacquiring seriousinfection. 
Thrombocytopenia mayincreasetheriskoflifeͲthreatening hemorrhage. Hemorrhagic orinfectious
complications duringtheexpected periodofaplasiamayresultindeath.

11.Miscellaneous. Alopeciaand
sterilityareexpectedcomplications oftheprogramasawhole. Cataract
development ispossibleafterTBIand/orsteroids. Deficiencies ofgrowth hormone, thyroidhormone, 
andsexhormones arepossibleafterTBI.Calcineurin inhibitors cancause transientgingivalhyperplasia, 
tremor,seizure,hypertension, headache, dysesthesia andhirsutism. Steroidtherapycanalsocontribute 
tofluidretention, easybruising,hypertension, asepticnecrosisofbone andincreased suscepti bilityto
infection. MMFcancausespontaneous abortions andbirth
defects.Hospi[INVESTIGATOR_059] duringconditioning 
andrecoveryperiodisexpectedtobe5Ͳ9weeks induration. 

 
IRB Approved 
Document Release Date:12/13/2017
Printed on 12/17/2017